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1.   INTRODUCTION 
 
Novel aspects for oral administration of therapeutic proteins and peptides are needed. 
Increasing the bioavailability of orally administered peptides and proteins is the main 
challenge, since the gastro-intestinal tract has various barriers for the delivery, such as 
proteolytic degradation resulting in degradation of the compound prior to absorption and 
the inability of the macromolecules to penetrate the intestinal cell wall (Zhou 1994). Thus 
the drug carrier system in oral delivery of therapeutic proteins has an important role 
(Langer 1998). The drug carrier protects the protein structure that is essential for 
preserving the bioactivity of the protein. Additionally, with controlled release prolonged 
delivery and maintaining concentration within therapeutic limits is possible and thus 
toxicity and systemic side effects can be reduced. Even though, protein and peptide drugs 
have typically been administered by injection, the oral route provides less invasive 
administration route and improves patient compliance. 
 
Polymer microspheres hold great potential as delivery systems for oral protein drug 
delivery (Freiberg 2004). Polymer microspheres can be used widely applied to many 
situations where continuous and controlled drug administration is essential and the use of 
microspheres for drug delivery is not limited to any specific illness. There are various 
microsphere preparation methods, however, the conventional bulk methods often result in 
polydisperse microspheres with poor encapsulation efficiencies.  
 
Microfluidic technology has various advantages as polymer microsphere preparation 
method (Utada et al. 2005). Precise manufacturing and gaining control over the process is 
possible. Exploring the possibilities of using microfluidic technology in polymer 
microsphere preparation is an interesting research topic for pharmaceutical sciences.  
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I    LITERATURE REVIEW 
 
2.  ORAL PROTEIN DRUG DELIVERY 
 
Oral delivery systems for proteins and peptides have been widely studied for the past few 
decades and yet challenges remain (Zhou 1994). For example, the production of 
therapeutic proteins is possible in large scales, but the bioavailability of the proteins is low 
when administered via the oral route. Proteins and peptides have large molecular size, and 
are very sensitive to enzymatic degradation, aggregation, adsorption, and denaturation, 
with short plasma half-life, ion permeability and immunogenicity (Saffran et al. 1986; Fix 
1996). When developing carrier systems for therapeutic proteins and peptides, providing 
protection against proteases and digestive enzymes in the gastrointestinal (GI) tract, and 
also enhancing the permeation and bioavailability of the encapsulated therapeutics, should 
be taken into account (Morishita and Peppas 2006). 
 
2.1   Challenges in oral delivery of proteins 
 
Various GI barriers inhibit the oral administration of proteins (Rekha and Sharma 2011). 
The acidic conditions in the stomach cause degradation of the proteins. In the small 
intestine, where drugs are mainly absorbed, the enzymatic activity of proteases is also 
higher than in any other part of the GI tract. Next, the enzymes in the intestine destroy the 
structure of the protein, such as aminopeptidase, trypsin, chymotrypsin, elastase, pepsin, 
and carboxypeptidase A and B. 
 
Poor absorption of macromolecules such as proteins and peptides limits the oral 
bioavailability of the therapeutics. Crossing the epithelial intestinal cell layer is possible 
via diffusion through the hydrophobic tight junctions by passive transport, via facilitated 
transcellular diffusion through the lipophilic absorptive cells, or via active carrier mediated 
transport systems or transcytosis (Ingemann et al. 2000). Proteins and peptides mostly 
absorb through the enterocytes or tight junctions of the epithelial intestinal cells (Rekha 
and Sharma 2011) (Figure 1).  
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Figure 1. The transport pathways for peptides and proteins across the intestinal cell 
epithelium (Rekha and Sharma 2011). 
 
Additionally, absorbed peptides and protein may undergo efflux from the cells due to their 
affinity to P-glycoprotein that decreases absorption rates and lowers the bioavailability (Li 
2001). The P-glycoprotein substrates also often undergo metabolism via the CYP3A4 that 
again lowers the bioavailability. Thus, in general, the oral bioavailability of most peptides 
and proteins is less than 1% (Mahato et al. 2003). 
 
Other physical barriers for proteins and peptides absorption are the size, charge and 
solubility constraints (Cox et al. 2002). Paracellular protein transport across the aqueous 
channels and tight junctions between the epithelial cells is limited due to the physical 
properties of the molecules. Size-dependent transport with constant size and charge 
indicates that various physical properties act in unison affecting the permeability of 
proteins and peptides. The positively charged peptides permeate better through the 
epithelial cells, indicating an interactive environment wherein the penetrating peptide and 
protein interacts with lipids and proteins lining the aqueous pores. Also this 
macromolecule permeability barrier is developed as the human being grows older (Udall et 
al. 1981). During a short period after birth, the GI tract is more permeable to 
macromolecules, and thus, the permeability of peptides and proteins across the GI tract of 
neonates is higher than that of the adult. 
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2.2   Applications for oral delivery of proteins 
 
The charge and solubility parameters of therapeutics can be changed by formulation and 
chemistry adjustments (Mahato et al. 2003). The solubility can be affected by using of a 
salt form or by covalent attachment of hydrophilic polymers such as PEG or hydrophobic 
lipids. Chemical modifications of peptides and proteins have been shown to improve also 
the stability and membrane penetration. These modifications can be done either by direct 
modification of exposed to the side-chain amino acid groups of the proteins (Murphy and 
óFágáin 1996) or through the carbohydrate part of the glycoproteins and glycoenzymes 
(Barbaric et al. 1988).There are formulation vehicles that are used to overcome different 
biological barriers within the GI tract, including hydrogels, emulsions, microemulsions, 
microparticles, nanoparticles, coated liposomes and mucoadhesive polymers. Also, 
protease inhibitors such as FK-448, which inhibits chymotrypsin (Fujii et al. 1985; 
Shinomiya et al. 1985), and absorption enhancers (Leone-Bay et al. 2001; Stoll et al. 2000) 
have been studied in order to enhance the oral drug delivery of proteins. 
 
As an example, cyclosporine A has been successfully formulated into oral protein drug 
dosage form (Sandimmun Neoral, Novartis). Cyclosporine is an atypical cyclic peptide 
which consists of 11 aminoacids, is highly hydrophobic, possesses significant oral activity 
as an immunosuppressant, and is also resistant to proteolytic degradation (White 1982). 
Cyclosporine A absorption takes place via transcellular diffusive route through the lipid 
membrane and it is substrate for P-glycoprotein (Saeki et al. 1993). Cyclosporine A has 
been formulated with peglicol-5-oleate, olive oil and ethanol at a ratio of 30:60:10 
followed by aqueous dilution for emulsification in order to avoid poor aqueous solubility, 
slow and incomplete absorption, and overall low oral bioavailability (Grevel 1986). The 
mean cyclosporine bioavailability is 30% in normal subjects and the absolute oral 
bioavailability varies from 5 to 90% in adult kidney transplant patients (Ptachcinski et al. 
1985). Cyclosporine A proves that production of commercially successful oral medicines 
of proteins and peptides drugs possible. Another remarkable example is the oral delivery of 
insulin, that is now also possible via oral route (Stanton 2013). The development process 
for oral insulin preparation has reached patenting stage at NovoNordisk. 
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3.   POLYMER MICROSPHERES 
 
Polymeric microcapsules hold great potential as oral drug delivery systems for therapeutic 
proteins (Freiberg and Zhu 2004). The preparation of the first polymer microspheres took 
place in the 1960s in order to better control the drug release: the first polymers used were 
silicone rubber (Folkman and Long 1964) and polyethylene (Desai et al. 1965). About a 
decade later the microsphere preparation with biodegradable polymers began (Mason et al. 
1976). In this literature review the focus is on the polymers used in this research poly(lactic 
acid) (PLA), poly(glycolic acid) (PGA) and poly(lactic-co-glycolic acid) (PLGA), however, 
a number of other biocompatible and biodegradable polymers suitable for medical 
applications also exist.  
 
3.1   Preparation of microspheres 
 
Various techniques for polymer microsphere preparation have been reported. Solvent 
evaporation technique to obtain oil-in-water (O/W) or water-in-oil-in-water (W/O/W) 
droplets is the most common method, and with this technique droplets are formed in an 
emulsion followed by evaporation the organic solvent (Freiberg and Zhu 2004; Jalil and 
Nixon 1989) (Figure 2). These emulsions can also be created by stirring the solutions with 
high speed homogenizers (Barbato et al. 2001) or sonicators (Tomar et al. 2011). After 
stirring, the microsphere polymerization takes place as the solvent is allowed to evaporate.  
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Figure 2. Solvent evaporation technique for preparing single or double emulsions in order 
to obtain polymer microspheres (Freiberg and  Zhu 2004). 
 
Other bulk methods for preparing polymer microspheres are the spray drying technique, 
the solution-enhanced dispersion method, the hot melt technique and coaservation. The 
spray drying method has been used widely for producing dry powders, granules or 
agglomerates, and can also be employed in the microsphere preparation processes 
(Bodmeier and Chen 1988). The solution-enhanced dispersion method enables the creation 
of microspheres without using organic solvents, forming stable microspheres with high 
encapsulation efficiencies by preparing microspheres using supercritical fluid (Bodmeier et 
al. 1995). With the hot melt technique the polymer used is melted, dispersed in a suitable 
dispersion medium and slowly cooled, and thus, forming microspheres (Mathiowitz and 
Langer 1987). This method is suitable for polymers with low melting points and for 
microspheres, which are susceptible to hydrolysis. Coaservation or phase separation 
consists of decreasing the solubility of the encapsulating polymer by addition of a third 
component to the polymer solution in an organic solution (Lewis 1990; Jalil and Nixon 
1990). In this process, the drug is dispersed in the polymer solution and coated by the 
coacervate. The process consists of phase separation of the polymer solution, adsorption of 
the coacervate around the particle containing the drug and solidication of the microspheres 
(Edelman et al. 1993). 
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The methods using shear in the emulsification process often result in polydisperse 
emulsions and to obtain small-size dispersions often requires shear forces that may degrade 
the peptides and proteins. Methods that produce more monodisperse particles are, for 
example, microporous membranes, where monodisperse emulsions are produced by 
extruding a coarse emulsion through porous glass membranes (Vladisavljević et al. 2006), 
droplets formation in microchannels (Sugiura et al. 2004), or microfluidics (Kim et al. 
2011; Kim et al. 2013; Datta et al. 2012; Duncanson et al. 2012a; Duncanson et al. 2012b) 
as discussed in this master’s thesis research work.  
 
The outcome of the polymer microsphere preparation process does not only depend on the 
production method, but also on the substances used in the process. Especially, the polymer 
molecular weight affects the qualities of the microspheres prepared (Park 1994). Shape, 
size and the degradation rate are connected to the molecular weight of the polymer. With 
microspheres that contain polymer chains of lower molecular weight, the quantity of the 
degradation products increases. The differences in the degradation profiles occur due to the 
differences in glass transition temperatures (Tg) and crystallinity associated with polymers 
of different molecular weights.  
 
The microspheres produced from double emulsions usually contain additional polymer 
with the water soluble drug in the inner phase, and thus, in the core of the microsphere 
(Freiberg and Zhu 2004) (Figure 3). The outer shell consists of polymer in the organic 
solvent that is later evaporated as the shell is polymerized.  
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Figure 3. Cross-section of the structure of a polymeric microsphere prepared by the 
solvent evaporation method from double emulsions (W/O/W) (Freiberg and Zhu 2004).  
 
3.2   Physicochemical properties of polymers used in this research work 
 
Aliphatic polyesters, such as poly(lactide), poly(glycolide), PCL and additionally their 
copolymers have been widely studied as biodegradable polymers for controlled drug 
delivery applications (Thombre and Cardinal 1990; Albertsson et al. 1992). The focus in 
this research was set on the following polymers due to their wide used in pharmaceutical 
industry. 
 
3.2.1   Poly(lactic acid), poly(glycolic acid) and poly(lactic-co-glycolic acid) 
 
Poly(lactic acid) (PLA) and poly(glycolic acid) (PGA) are thermoplastic aliphatic 
polyesters that are biodegradable and biocompatible (Wu 1995; Heller 1980; Kitchell and 
Wise 1985). Poly(lactic-co-glycolic acid) or poly(lactide-co-gycolide) (PLGA), is the 
copolymer of PLA and PGA (Figure 4). There are two forms of PLA: (1) an optically 
active stereoregular form (L-PLA) that has high regularity in its polymer chain, and (2) an 
optically inactive racemic form (D,L-PLA) that is an amorphous polymer because of the 
irregularities in the polymer chain structure (Tice and Cowsar 1984). PLGA prepared from 
L-PLA and PGA is crystalline while PLGA prepared from D,L-PLA and PGA is amorphous 
(Lewis 1990; Wu 1995). Lactic acid is more hydrophobic than the crystalline glycolic acid, 
and thus, PLGA copolymers that contain more lactide are less hydrophilic, absorb less 
water and degrade more slowly than PLGA copolymers which contain less lactide (Wu 
1995). The Tg of PLGA varies between 4060 °C depending on the ratio of lactide and 
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glucolide. The solubility of PLA, PGA and PLGA also varies according to the structure of 
the polymer. Generally, PLA, PGA and PLGA are soluble, for example, in 
dichloromethane, toluene and dimethyl sulfoxide. 
 
 
Figure 4. Structure of PLGA with a glycolic acid part (left) and lactic acid part (right) for 
the copolymer and the portions of these defines the properties of the copolymer (Langer 
and Vacanti 1993). 
 
The synthesis of PLA, PGA and PLGA can be conducted with direct polycondensation 
reaction of lactic or glycolic acid resulting in low molecular weight products (Fukuzaki et 
al. 1988). Other possible synthesis method is the ring-opening polymerization of cyclic 
dimers (Deasy et al. 1989). Thus, high molecular weight polymers are synthesized using 
metal catalysts. The intrinsic viscosity is directly related to the molecular weights of PLA, 
PGA and PLGA (Wu 1995). 
 
PLA, PGA and PLGA biodegrade correspondingly into lactic and glycolic acids (Wu 
1995). The biodegradation process presumably takes place purely through hydrolysis, yet 
differences have been found between in vitro and in vivo degradation rates, possibly due to 
some enzymatic activity (Lewis 1990; Wu 1995). The number of carboxylic end groups 
present in the PLGA chains increases during the biodegradation process, and thus, catalyze 
the biodegradation process. PLGA (50:50) hydrolyzes much faster than those containing 
higher proportion of either of the two monomers (Lewis 1990). The biodegradation process 
can create acidic microenvironment that can cause issues with biocompatibility and protein 
degradation (Fu et al. 2000). Since PLGA is one of the first FDA approved polymers, it has 
been widely used in various studies where polymer microspheres have been successfully 
manufactured with vancomycine (Atkins et al. 1998), polypeptide (Li et al. 1995) and with 
bovine insulin (Uchida et al. 1997). 
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PLGA microspheres have also been used in the development of oral vaccines. Ovalbumin 
as a model antigen has been successfully administered orally from PLGA particles 
(Challacombe et al. 1997; Uchida et al. 1994). In addition, also microspheres in oral 
administration of tuberculosis vaccinations have been reported (Vordermeier et al. 1995). 
 
3.2.2   Polycaprolactone 
 
Polycaprolactone, poly (ε-caprolactone) or poly (epsilon-caprolactone) (PCL), is a semi-
crystalline and hydrophobic polymer (Chandra and Rustgi 1998). The melting point of 
PCL is 60 ºC and is soluble in dichloromethane, chloroform, carbon tetrachloride, benzene, 
toluene, cyclohexanone, acetone, 2-butanone, ethyl acetate, dimethylformamide and 
acetonitrile (Coulembier et al. 2006). The Tg of PCL is 60 °C and the melting point is 
between 59 and 64 °C (Hayashi 1994). PCL is biocompatible and biodegradable (Pitt 1990; 
Chen et al. 2000). Degradation of PCL is an autocatalyzed reaction, where the liberated 
carboxylic acid end groups catalyze the hydrolysis of additional ester groups (Pitt 1990). 
 
There are two methods used to prepare PCL: (1) though a free radical ring-opening 
polymerisation from 2-methylene-1-3-dioxepane, and (2) more commonly by using a ring-
opening polymerisation from ε-caprolactone using a variety of anionic, cationic and 
coordination catalysts (Pitt 1990). The ring-opening polymerization is catalyzed with 
stannous actuate and the molecular weight can be controlled with low molecular weight 
alcohols (Storey and Taylor 1998) (Figure 5). Various molecular sizes of PCL are 
available and the bigger the molecular weight is the less crystalline is its structure 
(Chandra and Rustgi 1998). The molecular weight can vary from 3,000 to 80,000 g/mol 
(Hayashi 1994). 
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Figure 5. Example of the ring-opening polymerization of PCL with anionic catalyst (R

) 
(Labet and Thielemans 2009). After this initial reaction the anionic catalyst is removed and 
the PCL chain is complete.  
 
PCL has been widely used in the preparation of microparticles for drug delivery (Tomar et 
al. 2011; Somavarapu et al. 2005; Scala-Bertola et al. 2012, Natarajan et al. 2011) (Figure 
6). PCL microspheres have been mainly manufactured with the traditional emulsion 
methods containing, for example, BSA (Bolzinger et al. 2007; Coccoli et al. 2008), taxol 
(Dordunoo et al. 1995), cyclosporine (Aberturas et al. 2002), ketoprofen (Guzman et al. 
1996), and insulin (Shenoy et al. 2003). Additionally, microfluidic preparation of PCL 
microspheres has been studied without loading the particles (Liu et al. 2009). 
 
 
Figure 6. PCL particles prepared from PCL with bulk methods (a) PCL particles prepared 
with vigorous magnetic stirring and 2.5 % PCL in DCM as the middle phase (Scala-
Bertola et al. 2012) and (b) PCL particles prepared using ultrasonic bath and 1.7 or 3 % of 
PCL in DCM as the middle phase that forms the shell (Coccoli et al. 2008). 
 
PCL also has good blend-compatibility and various co-polymers have been prepared from 
PCL (Chandra Rustgi 1998; Chang et al. 1986). PCL has also been combined, for example, 
with PLA, PLGA, cellulose propionate and cellulose acetate butyrate. The modifications 
affect the release kinetics of the microparticles.  
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3.3   Characterization methods for microspheres 
 
In vitro characterization of the microspheres is essential for the early stages of drug 
product development (Gibson 2001). Resources in the drug development process can be 
significantly saved when the basic characterization of the product is done thoroughly in the 
beginning. The in vitro characterization in the early stages consists of evaluating the 
particle size, stability, encapsulation efficiency, surface properties and drug release. The 
particle size can be observed with optical microscopy or more advanced techniques, such 
as Coulter counter (Gee and Bauder 1986) or light blocking methods (Gibbs 1982). The 
drug release profiles are often affected by the size distribution and in many cases the rate 
of drug release has been found to decrease with increasing sphere size (Narayani and Rao 
1994; Akhtar and Lewis 1997). 
 
With fluorescent samples, characterization in terms of the content of the particles, by 
confocal microscopy is useful. This form of microscopy is an optical imaging technique 
that uses point illumination and a spatial pinhole to eliminate out-of-focus light in the 
sample that are thicker than the focal plane
 
(Pawley 2006). With confocal microscope it is 
possible to observe the sample on a depth level at a time and when using fluorescent agents 
in the samples, lasers can be employed to produce emission-excitation spectra from the 
sample. Stability studies are conducted for the products in stressed conditions in order to 
evaluate the performance of the product over the preservation periods (Gibson 2001). 
 
Scanning electron microscopy (SEM) is also used to observe the morphology of an object 
and can be used to evaluate the surface properties and the particle size of the microspheres 
(Hamley 2007). When using SEM, an electron beam is scanned across an object, knocking 
secondary electrons out of its surface atoms. The secondary electrons are then detected 
with appropriate detector. The actual image is produced using this data.  
 
Another important characterization parameter is the encapsulation efficiency. Increasing or 
controlling the encapsulation efficiencies is desirable, because it can prevent the loss of 
expensive medicines and it can help to extend the duration and dosage of treatment (Gupta 
and Kumar 2001). The drug content of the encapsulated microspheres can be described by 
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two quantities: the total amount of drug employed minus the amount of unloaded drug. 
From the results of the encapsulation efficiency studies the preparation method can be 
evaluated in terms of the ability to incorporate the model drug into the microspheres 
(Judefeind and De Villiers 2009). The encapsulation efficiency is used to evaluate the 
performance of the drug delivery system and to compare the quality of different 
formulations.  
 
Dissolution testing is also an important part of drug product development (Lee et al. 2008). 
Dissolution testing provides data regarding the rate and extent of drug absorption in the 
body and it can assess the formulation principles on the release properties of a drug 
product. For conventional dosage forms there are a set of procedures for the drug release 
tests (Siewert et al. 2003). For novel dosage forms, in which the formulation design and the 
physicochemical properties vary, the development of the dissolution test system is more 
demanding. However, the general principles of dissolution tests for solid oral dosage forms 
should also be applicable to in vitro drug release tests for novel dosage forms, such as 
microparticles. The goal of the dissolution tests is to use the test for the biopharmaceutical 
characterization of the drug product, and for ensuring consistent product quality within a 
defined set of specification criteria. 
 
Polymeric microspheres have also been widely characterized in vivo and in vitro in order to 
establish an in vitro–in vivo correlation. For example, the in vivo results using PGLA 
microsphere systems have been obtained from rats for the release of nifedipine (Sandstrap 
et al. 1999; Tuncay et al. 2000). 
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4.   DROPLET-BASED MICROFLUIDICS 
 
With microfluidic devices it is possible to mix immiscible liquids with precise control 
(Squires and Quake 2005). The microfluidic technology has various advantages, 
particularly the ability to create actually three-dimensional flows (Utada et al. 2005). This 
makes the precise manufacturing process possible and enables gaining the control over the 
immiscible fluids. 
 
4.1   Physics of microfluidics 
 
The droplet formation in microfluidic devices is based on jetting to dripping transition and 
by taking advantage of the hydrodynamic instability (Powers et al. 1998). With the jetting 
to dripping transition the drop formation involves a balance between the viscous drag of 
the coaxial fluid that pulls on the drop and the surface tension forces (Umbanhowar et al. 
2000). The surface energy is decreased as the jet breaks into drops, and thus, the drop 
formation can be understood via the Rayleigh-Plateau instability (Squires and Quake 2005; 
Utada et al. 2007). The stream breaks into drops as the Laplace pressure increases within 
the thinner parts of the stream. The Laplace pressure is the internal pressure of water 
caused by the curvature of the interface. This high pressure pushes the fluid within the jet 
to either side causing the thin region to become thinner and form the drops. Additionally, 
the jetting to dripping transition is affected by the capillary number that is the balance 
between the force caused by the viscous drag and the force caused by surface tension. 
When there is little viscous drag and the capillary number is low, the Weber number is 
necessary to describe the balance between the inertial and the surface tension forces. Then, 
the inertial force of the fluid must overcome the surface tension forces, and thus, leading to 
pinch-off and to create the drops. 
 
The modelling of the behaviour of fluids in microscale can also be described with 
additional dimensionless numbers, as described representatively in the review article by 
Squires (Squires and Quake 2005) (Table 1).  
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Table 1. The dimensionless numbers that are used to describe the physics of microfluidics 
(Squires and Quake 2005): ρ is the density, L0 is the length scale, U0 the is the flow 
velocity, η the is shear viscosity, D is the diffusivity, γ the is surface tension, τp is the 
polymer relaxation time, τflow is the oscillation time, h is the shortest dimension setting the 
shear rate, Ub is the buoyant velocity scale, and β is a slip length of order. 
 
 
The Reynolds number (Eq. 1), relates the inertial forces to the viscous forces; the Péclet 
number (Eq. 2) relates the convection to diffusion; the capillary number (Eq. 3) relates the 
viscous forces to the surface tension; the Deborah (Eq. 4), Weissenberg (Eq. 5), and the 
elasticity numbers (Eq. 6) express the elastic effects; the Grashof (Eq. 7) and the Rayleigh 
(Eq. 8) numbers relate the transport mechanisms in the buoyancy-driven flows; and the 
Knudsen number (Eq. 9) relates the microscopic to the macroscopic length scales (Squires 
and Quake 2005). 
 
Using the Reynolds number the magnitude of the inertial and the viscous force densities 
are compared (Squires and Quake 2005). The viscous force densities result from gradients 
in viscous stress. When it comes to the scale used in microfluidics, the Reynolds number is 
often small enough for the inertial effects to be irrelevant. Thus, the viscosity has a greater 
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effect when it comes to fluid behaviour in microfluidics. The viscous forces typically 
overwhelm the inertial forces and this is why the flow is linear. The Péclet number 
referrers to the relative importance of convection to diffusion and describes how far down 
the channel must the fluids flow before the channel is homogenized. This diffusive mixing 
can be desirable depending on the application. The Péclet number is more relevant when 
the fluids used in the microfluidic system are miscible.  
 
The capillary number is important when the fluids in the microfluidic system are 
immiscible (Squires and Quake 2005). Between immiscible fluids the surface tension 
affects the dynamics of the free surface, and due to the Rayleigh-Plateau instability, the 
stream of the fluid breaks into drops (De Gennes et al. 2004). Thus, microfluidic devices 
can be used to create controllable droplet emulsions in immiscible fluids (Thorsen et al. 
2001). Competing stresses drive the interface.  The surface tension works to reduce the 
interfacial area and the viscous stress works to extend and drag the interface downstream. 
The droplets form as the interphase is destabilized. The capillary forces can also be used to 
manipulate and transport fluids with free surfaces, and usually modifying the interfacial 
forces disrupts the balance and causes motion (Squires and Quake 2005). 
 
The Weissenberg and Deborah numbers help to evaluate the elastic component to the fluid 
caused by the dissolved polymers (Squires and Quake 2005). Adding polymers enriches 
the flow behaviour. Weissenberg number describes the spring forces balancing the 
Brownian forces to give a characteristic polymer size and Deborah number describes the 
time scale characteristic of the flow geometry. The flow time scale can be long or short 
compared with the polymer relaxation time resulting in a dimensionless ratio. The 
elasticity number evaluates the change of the elastic effects as the flow velocity increases. 
With the increase of the elasticity number also the Weissenberg and Deborah numbers 
increase. In addition, Reynolds number increases in the same way and the inertial effects 
become more important. The Grashof and Rayleigh numbers help understand the effects 
that density differences have on the fluid behaviour. The Grashof and Rayleigh numbers 
compare the same fundamental effects as the Reynolds and Péclet numbers. The Knudsen 
number matters when the fluid cannot be treated as a continuum. Non-continuum effects 
have an increasingly important role as the Knudsen number increases. 
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4.2   Microfluidic devices  
 
Microfluidic devices at Prof. Weitz’s laboratory are hand-made glass capillary devices 
(Duncanson et al. 2012a; Chu et al. 2007; Shum et al. 2011; Kim and Weitz 2011), 
similarly to the microfluidic devices that have been manufactured in other research works 
(Liu et al. 2009), or poly(dimethylsiloxane) (PDMS) devices (Abate and Weitz 2009; 
Thiele et al. 2010) which are manufactured with soft lithography (Whitesides and Stroock 
2001). Soft lithography at Harvard University takes places in the Center for Nanoscale 
Systems and the manufacturing is based on automated manufacturing systems employing 
matrixes made for each device design.  
 
Microfluidic devices can employ whether coaxial flow, hydrodynamic flow-focusing or 
combination of these two. With co-flow (Figure 7) one fluid flows on the outside of the 
circular capillary through the square capillary and the other flows through the inner 
circular capillary (Umbanhowar et al. 2000). The result is a coaxial flow of the two fluids 
that easily form drops. The alternative for co-flow is flow-focusing of the inner fluid by the 
outer fluid (Gañán-Calvo and Gordillo 2001) (Figure 7). The outer fluid is introduced into 
the device as in the co-flow device, yet the inner fluid is being introduced from the 
opposite side and both fluids are collected, and exit through the cylindrical capillary. The 
process is basically the same as with the co-flow device design, but one fluid is flowing in 
the opposite direction and is hydrodynamically focused through the narrow orifice by the 
outer fluid. The advantage of this method is the production of a stream that is narrower 
compared to the orifice size. 
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Figure 7. (a) A co-flow microcapillary device for producing single emulsion droplets () 
and (b) a flow-focusing microcapillary device for making single emulsion droplets (Utada 
et al. 2007). 
 
By combining co-flow and flow-focusing, the preparation of more complex materials is 
possible (Utada et al. 2005). The designs of these devices are more complicated and perfect 
alignment of the tapered capillaries is required (Figure 8). Drops are thus created at the 
orifice from a coaxial flow of two fluids. 
 
 
Figure 8. Microfluidic device that combines co-flow and flow-focusing thus creating 
double emulsion droplets (Utada et al. 2007). 
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The process for double emulsions is completely scalable (Chu et al. 2007; Wang et al. 
2011). The desired number of layers can be added to the procedure by repeating the flow-
focusing and co-flow parts to the devices used (Figure 9). However, the more complex the 
emulsion structure is, the more control is needed for the process to succeed (Utada et al. 
2007). The process can be adjusted by controlling the size and number of drops. Also, a 
large number of droplets can be encapsulated and stabilized within another droplet (Adams 
et al. 2012). Preparing more complex structures is generally more time consuming than 
preparing single emulsions.  
 
 
 
 
Figure 9. Multiple emulsion droplets with varying structures (Wang et al. 2011). 
 
Besides repeating the structures of the device to obtain multiple emulsions, it is also 
possible to fabricate one-step emulsification of multiple concentric shells capillary 
microfluidic devices (Kim and Weitz 2011) (Figure 10). The formation of a stable coaxial 
interfaces and subsequent breakup provides a facile way to produce monodisperse multiple 
emulsion drops of high order and has potential as advanced microcapsules. 
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Figure 10. Advanced microcapsules manufactured by a single-step emulsification process 
(Kim and Weitz 2011). 
 
Similar functions are achieved with different designs of PDMS devices (Abate and Weitz 
2009) (Figure 11). The channels contain certain number of T-junctions. Engineering the 
channels carefully optimizes the drop formation and enables controlling the droplet size 
and production of the monodisperse droplets. Also, the droplet production process with 
PDMS devices is scalable and it is possible to specify the multiple emulsion order. As the 
devices are prepared lithographically, the wettability of the channels in the device can be 
alternated to optimal for the production of the multiple emulsions using hydrophobic or 
hydrophilic coating.   
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Figure 11. Channels in PDMS devices. By adding T-junctions multiple emulsions can be 
prepared, modified from (Abate and Weitz 2009). Photomicrographs of (a) single, (b) 
double, (c) triple, (d) quadruple and (e) quintuple emulsion drop maker arrays. The scale 
bars indicate 100 µm. 
 
4.3   Applications of microfluidics 
 
With microfluidic technology it is possible to independently choose the chemical 
compositions and structures of the prepared particles (Duncanson et al. 2012b). The 
modification of the particle properties is done with the selection of fluids to certain device 
design. With microfluidics synthesizing a range of microparticles with distinct composition 
and structure is possible. Next, the applications of microfluidics done at Weitz’s laboratory 
at School of Engineering and Applied Sciences at Harvard University are described.  
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4.3.1   Microfluidics used to produce microparticles 
 
Various polymeric microparticles as single emulsion droplets have been prepared with 
microfluidics, for example, using PLA in a flow-focusing device (Vladisavljević et al. 
2012; Duncanson et al. 2012c). With these processes the monodispersity and the size of the 
particles are mainly adjusted with the phase flow rates. With PDMS devices the 
preparation of highly monodisperse, sub-micrometre conjugated polymer particles has also 
been reported (Kuehne and Weitz 2011). In addition to the flow rates, the particles size can 
be controlled by the polymer concentration with as small particles as 150 nm to 2 µm. As 
additional layer, usually W/O/W is added to the emulsification, and the process creates 
hollow polymer microspheres (Duncanson et al. 2012b; Liu et al. 2009). Double emulsion 
for preparing microspheres with ultra-thin shells can be created using biphasic flow in the 
inner capillary of the glass capillary devices combining co-flow and flow-focusing (Kim et 
al. 2011; Kim et al. 2013a) 
 
Additional elements such as size-tunable pores can be added to the microparticles prepared 
as emulsion droplets by microfluidics (Duncanson et al. 2012c). Tunable active release 
mechanisms can also be added to the microparticles (Abbaspourrad et al. 2013). These 
particles are triggered by a plasticizing stimulus that indicates a phase change transition of 
the polymeric membrane from a solid form to a fluidized form. The absorption of the 
liquid plasticizing stimulus, a solid-to-liquid phase change is initiated within the capsule 
membrane. This enables controllable release kinetics as the cargo is actively driven out of 
the microcapsule through a defect at the particle shell. Tuning of the fluidity of the 
membrane is possible by altering the amount of plasticizing stimulus. Stimuli-responsive 
microcapsules that selectively release their contents through head-to-tail depolymerization 
of poly(phthalaldehyde) have been prepared with flow-focusing microfluidic technology 
(DiLauro et al. 2013). Poly(phthalaldehydes) depolymerize completely from head-to-tail in 
response to fluoride, which provides an amplified response to the applied chemical signal 
and the rate of the response can be tuned both by varying the length of the polymer and the 
thickness of the shell wall. 
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4.3.2   Thermosensitive products used in microfluidics 
 
Adding another fluid input downstream by introducing an activator or accelerator for the 
gelation reaction can be used to produce different kinds of gels (Utada et al. 2007). Taking 
advantage of the fine control of the mixing fluids, creating a gel that shrinks in response to 
heat is also possible.  
 
Droplet-based microfluidics can be used to produce thermosensitive poly(N-
isopropylacrylamide) (pNIPAm) gel particles (Shah et al. 2008). In addition, with the 
microfluidic preparation technique controlling both outer dimensions and inner 
morphology of the particles is possible. These techniques are applicable for the synthesis 
of particles of a variety of chemical compositions and for the generation of higher order 
supraparticles using directed assembly of colloidal particles in droplets. Also, pNIPAm 
microparticles have been produced with microfluidics and these thermosensitive structures 
enable more accurate drug release properties for advanced drug delivery applications 
(Duncanson et al. 2012b).  
 
4.3.3   Polymersomes used in microfluidics 
 
A variety of polymersomes, vesicles with a membrane composed of a bilayer of 
amphiphilic block-co-polymers (Discher et al. 1999), have been prepared with the glass 
capillary devices. Multi-compartment polymersomes can be used for storing multiple drugs 
in a single carrier and for enabling simultaneous release of two active agents (Zhao et al. 
2011). Polymersomes can be stabilized with hydrogel cores and induced UV-
polymerization (Kim et al. 2013b). Polymersomes for triggered release can be produced 
using photo- and thermo-sensitive polymers (Amstad et al. 2012). Polymersomes with 
potential for extremely accurate content release can be created using a capillary 
microfluidic device using W/O/W double emulsion drops with the middle oil phase 
containing a mixture of thermoinsensitive amphiphiles, thermosensitive amphiphiles, and 
photothermal gold nanoparticles. Additionally, polymersomes can also be used as artificial 
cells in biomimetic studies to model protein expression and aggregation more effectively 
than it is possible to model with artificial cells produced with other methods (Martino et al. 
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2012). These artificial cell structures can be specifically modified with microfluidics to 
obtain optimized modelling properties. For example, in the study of Martino et.al in 
additional homopolymer layer was included in the shell to enhance stability and prevent 
protein aggregation into the shell structures.  
 
4.3.4   Applications for cells using microfluidics 
 
The encapsulation of single cells is possible with droplet based microfluidics (Köster et al. 
2008). Thus, it is possible to encapsulate, incubate, and manipulate individual cells in 
picoliter aqueous drops in a carrier fluid and using drop-based microfluidics to create 
preconditions for single cell experiments (e.g., as screening for monoclonal antibodies). 
Microgel gelation for micrometer-sized hydrogel particles that contain living cells without 
using reaction involving free radicals can be produced with microfluidics (Rossow et al. 
2012). Thus, the viability of the cells is ensured and the microfluidic technology offers 
additional advantages for cell cultural systems.  
 
High-throughput analysis and sorting of single cells is also possible with microfluidics 
(Mazutis et al. 2013). Compartmentalization of single cells in droplets enables the analysis 
of proteins released from or secreted by cells, and thus, overcoming the limitations of 
traditional flow cytometry and fluorescence-activated cell sorting. The microfluidic 
systems are easily adapted for screening other intracellular, cell-surface or secreted 
proteins and for quantifying catalytic or regulatory activities. 
 
4.3.5   Other applications of microfluidics 
 
Fabrication of liquid crystals by making the middle fluid a liquid crystal mixed with 
chloroform, lowers its viscosity and makes it isotropic (Nelson 2002). After the shell is 
formed the chloroform evaporates and a shell of liquid crystal is produced. Predicting a 
variety of different defect structures results in making a shell of liquid crystal. Also, gas 
filled particles, bubbles and anti-bubbles can be manufactured with droplet-based 
microfluidic production (Duncanson et al. 2012a). The generation of water-in-water (w/w) 
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jets and emulsions by combining droplet microfluidics and aqueous two-phase systems is 
also possible (Shum et al. 2012). 
 
Microfluidics can also be used for observing various phenomena, for example, the 
breaking behaviour of droplets (Chen et al. 2011) or buckling of colloidal capsules in order 
to create advanced capsule shells (Datta et al. 2012). Another application for microfluidic 
drop technologies is the use of the drops as isolated microreactors for chemical reactions 
(Utada et al. 2007). Water-based assays are most commonly used and suitable also for bio-
assays. For example, synthesizing mesoporous hydroxyapatite is possible using double 
emulsion droplets as microreactors (Shum et al. 2009). Double emulsion droplets are 
highly versatile microreactors, because offer the combined advantages of both shielding 
the reactants and on-demand addition of reactants, and also enable simple visualization of 
the hydroxyapatite formation process as well as control over the porosity in the 
hydroxyapatite being synthesized. Stabilizing the drops against coalescence while 
preventing any of the contents of the drops from dissolving in the continuous phase is a 
challenge when preparing these microreactors.  
 
Scaling up of the materials produced by microfluidics is possible up to the range of a few 
kilograms per day (Utada et al. 2007). The scaling up possibility is based on the use of a 
large number of the aligned capillaries in PDMS devices, operating in parallel and the 
primary applications for such encapsulation materials would likely be for high-value-added 
materials. 
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5.   AIMS OF THE STUDY  
 
The research conducted in this master’s thesis had four main goals: 
 
(1) To apply droplet based microfluidics on polymeric microsphere preparation 
process, and thus, to employ the advantages that microfluidic technology offers in 
terms of producing stable, monodisperse double emulsion (W/O/W) droplets with 
high encapsulation efficiency of therapeutic molecules.  
 
(2) To determine suitable formulations for microfluidics and to study the general 
limitations concerning the formulations, as well as to adjust them to the use with 
biocompatible and biodegradable materials.  
 
(3) To control the preparation process of the formulations and to establish a stable and 
precise preparation system, and thus, to create a new paradigm for microsphere 
production and to produce sophisticated droplets that are superior to those 
manufactured with conventional bulk methods.  
 
(4) To characterize the droplets, to prove their quality and to load the droplets with 
therapeutic proteins in order to create templates for enhanced oral protein drug 
delivery using the microfluidic process developed as mild processing option 
suitable for protein drug product preparation.  
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II    EXPERIMENTAL PART 
 
6.   MATERIALS AND METHODS  
 
The following reagents or solvents were used in the experimental part of this work (Table 
2). The reagents or solvents are listed with the essential information, purity (if provided) 
and manufacturer. 
 
Table 2. List of reagents and solvents used in this work. 
Reagent or solvent Purity Manufacturer 
Trimethoxy(octadecyl)silane 90 % Sigma-Aldrich, U.S. 
2-[methoxy(polymethyleneoxy)propyl] 9-12 
trimethoxysilane 
90 %  
 
Gelest Inc., Netherlands 
 
Poly(vinyl alcohol) (PVA) 87-89 % hydrolyzed, 
Mw 13,00023,000 
 
Sigma-Aldrich, U.S. 
 
Poly(D,L-lactide-co-glycolide) (PLGA) 85:15,   
Mw 50,00070,000 
 
Sigma-Aldrich, U.S. 
 
Poly(D,L-lactide-co-glycolide) (PLGA) 50:50, 
i.v. 0.50.65 
 
Polysciences Inc., U.S. 
 
Poly(L,D-lactic acid) (PLA), i.v. 0.2 
 
Polysciences Inc., U.S. 
Polyethylene glycol (PEG) 6000, Mw 5,0007,000 
 
Fluka Analytical, Germany 
Polycaprolactone (PCL), Mw 70,00090,0000 
 
Sigma-Aldrich 
Tween® 20 
 
Sigma-Aldrich, U.S. 
Dichloromethane (DCM) ≥ 99.8 % Sigma-Aldrich 
Ethyl acetate (EtOAc) ≥ 99.5 % Sigma-Aldrich, U.K. 
Sodiumchloride (NaCl) 
 
>99 % 
≥ 99.5 % 
BHD, U.S. 
Fluka Analytical, Germany 
Nile red 
 
Sigma-Aldrich, Germany 
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FITC-dextran, Mw 10,000 
 
Molecular Probes, U.S. 
3,4,9,10-perylene-tetracarboxylic dianhydride  97 % Sigma-Aldrich, Germany 
β-galactosidase (from Aspergillus oryzae)  
10.3 units/mg 
 
Sigma-Aldrich, Japan 
 
Salbutamol sulphate 
 
Alfa Aesar, U.S. 
Bovine serum albumin (BSA) ≥ 96 % Sigma-Aldrich, Germany 
2-nitrophenyl β-D-galactopyranoside (ONPG) >98 % Sigma-Aldrich, Switzerland 
2-mercaptoethanol ≥ 99 % Sigma-Aldrich, Germany 
Magnesium chloride hexahydrate (MgCl2) ≥ 99 % Sigma-Aldrich, Japan 
Sodium carbonate (NaCO3) ≥ 99.5 % Sigma-Aldrich, U.S. 
Methanol (MeOH) HPLC gradient grade ≥ 99.9 % BDH, EC 
Acetonitrile (ACN) HPLC gradient grade ≥ 99.9 % BDH, EC 
Trifluoroacetic acid (TFA) 99 % Sigma-Aldrich, Germany 
Potassiumdihydrophosphate (KH2PO4) 
 
99.4 % 
> 99.5 % 
Mallinckrodt, U.S. 
Riegel-de Haën, Germany 
Potassium chloride (KCl) ≥99 % Sigma-Aldrich, Germany 
Disodium phosphate monobasic (Na2HPO4) >98 %  Sigma-Aldrich, Germany 
Sodiumhydroxide (NaOH) ≥ 98 % Sweden 
Hydrochloric acid (HCl) 1M 
 
BDH, France 
 
The following solutions were prepared for the experiments. The collection media for the 
emulsion droplets was made with 0.2922 g of NaCl in 100 mL of MQ-water (50 mM) or 
with 0.911 g of NaCl in 100 mL of water (156 mM).  
 
The activity assay solution was prepared as a mixture containing 0.05 mL of 68 mM 
ONPG solution, 0.05 mL of 30 mM MgCl2 solution, 0.05 mL of 3.36 M 2-mercaptoethanol 
solution and 1.3 mL of 100 mM saline phosphate buffer solution (PBS). PBS buffer 
consisted of 0.8 g of NaCl, 0.02 g of KCl, 0.144 g of Na2HPO4 and 0.024 g of KH2PO4 in 
100 mL of MQ-water. 1 M HCl was used to adjust the pH of the solution to 7.4.  
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The mobile phases used in the HPLC experiments were as follows:  
0.1 % TFA in MQ-water was prepared by mixing 1 mL of TFA in MQ-water and filtering 
before use. PBS (25 mM) was prepared by adding 3.9 g of KH2PO4 to 1000 mL of water, 
adjusting the pH to 3.0 and filtering the solution before use. Buffers for dissolution tests 
were prepared according to the European Pharmacopoeia, 7
th
 edition. PBS (100 mM) was 
prepared by mixing 0.68 g of KH2PO4 and 0.14 g of NaOH to 100 mL of water and 
adjusting the pH to 7.2. HCl buffer (100 mM) was prepared by mixing 8.5 mL of 1 M HCl 
and 0.27 g of NaCl in 100 ml of MQ-water and adjusting the pH to 1.2. 
 
6.1   Microfluidic devices and production of droplets 
 
In the following experiments droplets were produced with three different designs of 
microfluidic glass capillary devices. Each design was optimized to prepare the desired type 
of droplets with certain flow properties. First, double emulsion droplets were produced 
with two tip glass capillary device designed for double emulsions. Then, a single emulsion 
was produced with one tip glass capillary device. Finally, double emulsion droplets were 
produced with glass capillary device designed for biphasic flow.  
 
Devices were assembled on glass slides and they consisted of square capillaries (outer 
diameter = 1.5 mm; inner diameter = 1.05 mm; Harvard borosilicate square tubing; 
Atlantic International Technology, U.S.) and cylindrical capillaries (outer diameter 1.0 mm; 
inner diameter 580 µm; borosilicate glass tubing; World Precision Instruments Inc., U.S.). 
Cylindrical capillaries were placed inside the square capillaries and aligned with them. 
Capillaries were glued on the glass slide with epoxy glue and the needles (Type 304 SS 
Dispensing Needle 20 Gauge, U.S.) were set at the ends of the capillaries as inlets and also 
glued on the glass slides (Figure 12). 
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Figure 12. Assembling process of microfluidic glass capillary device for biphasic flow; 1) 
square capillaries are cut; 2) square capillaries are glued on the glass slide; 3) cylindrical 
capillaries are pulled and placed in the square capillaries and after that the alignment is 
glued on the glass slide; 4) stretched cylindrical capillary for inner phase is added; 5) 
needles as inlets are added; and 6) glued carefully on the glass slide.  
 
Cylindrical capillaries were pulled with a Flaming/Brown micropipette puller (Model P-97, 
Sutter Instrument Co., U.S.) to obtain tapered tips and to form tips of desired diameter. 
Tips were formed under the following parameters of the micropipette puller: heat = 260 C°; 
pull = 3 N/m; velocity = 3 m/s; and time = 150 s. The largest diameter possible to obtain 
with the micropipette puller was 40 μm. When larger diameters were needed the tips were 
carefully sanded with fine sand paper (P2000).  
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Cylindrical capillaries were coated with hydrophilic or hydrophobic coating, corresponding 
to whether they contained the water or the oil phase. Tips were dipped in either the 
hydrophobic trimethoxy(octadecyl)silane (Sigma-Aldrich, U.S.) or the hydrophilic 2-
[methoxy(polymethyleneoxy)propyl] 9-12 trimethoxysilane (Gelest Inc., Netherlands) and 
were dried with pressurized air after 30 minutes of the coating process.  
 
Emulsion phases (either W/O or W/O/W) were pumped into the glass capillary devices 
with syringes and Harvard pumps (Harvard Apparatus Hollston, U.S.). Syringes were 
attached to the inlets with plastic tubing (PE5 0.86 mm x 1.32 mm, Scientific Commodities 
Inc., U.S.). Flow rates were controlled with Harvard pumps starting with higher flow rates 
in order to form the interphase in the correct location and then gradually reduced to start 
the droplet formation. Flow rates were optimized for each formulation and each device. 
 
The drop formation was observed with optical microscopes (Leica, Germany and Edmund 
Scientific, Germany) and high speed cameras (Phantom High Speed Cameras: V7, V7.3, 
V9; Vision Research Inc., U.S.) (Figure 13). Recordings with the cameras were done with 
250 time deceleration, the videos showing the droplet formation phenomenon 250 times 
slower than in actuality.   
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Figure 13. Microfluidic droplet production: (a)(c) Harvard pumps with syringes 
containing inner, middle and outer phases; (d) microfluidic device and optical microscope; 
(e) high speed camera (covered with tin foil); and (f) computer for monitoring the process.   
 
The phases were filtered (Acrodisc Syringe Filter, 0.45 µm Super Membrane, Life 
Sciences, U.S.) before the preparation process. Glass capillary devices were washed with 
MQ-water before the preparation process to remove all the air from the capillaries. Droplet 
formation was monitored throughout the process and possible problems were recorded.   
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6.2   Formulation screening study 
 
6.2.1   Double emulsion with two tip glass capillary devices 
 
The two tip glass capillary device consisted of three inlets and two tips in the middle of the 
device (Figure 14). This device combined co-flow and flow-focusing and it was ideal for 
producing monodisperse double emulsion droplets with rather thick shell as a continuous 
process. The inner phase flows through the cylindrical capillary with smaller tip, and the 
middle and outer phases flow to opposite directions in the square capillary. Droplets were 
collected in a vial containing water or collection media with osmolarity corresponding to 
the osmolarity of the inner phase. Osmolarity was adjusted by measuring the osmolarity of 
the inner phase with an osmometer (The Advanced Micro Osmometer, Model 3300, 
Advanced Instruments Inc., U.S.). 
 
 
Figure 14. Two tip glass capillary devices for preparing double emulsion droplets: (a) inlet 
for the inner phase; (b) inlet for the middle phase; (c) hydrophobic and hydrophilic tips 40 
and 200 µm, respectively, with the latter being the collection tube; (d) inlet for the outer 
phase; and (e) outlet for double emulsion droplets.  
 
Within the square glass capillary, the tips of the cylindrical capillaries were at 80 µm 
distance from each other (Figure 15). Flow rates were adjusted so that the interphase was 
formed at the tip of the cylindrical capillary of the inner phase. The flow rates were varied 
according to the formulation used as follows: 50010,000 µL/h in the outer phase, 
758,000 µL/h in the middle phase, and 505000 µL/h in the inner phase. 
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Figure 15. Flows of the phases in the two tip glass capillary devices for double emulsion 
formation (W/O/W). The inner phase flows through the cylindrical capillary, and the 
middle and outer phase in the square capillary where they form an interphase at the tip of 
the cylindrical capillary of the inner phase. Double emulsion droplets are formed at this 
interphase.  
 
 
The droplet preparation process started with the higher flow rates and the rates were 
gradually decreased to very slow rates to allow the jetting to dripping transition. In the 
beginning of the process, higher flow rates were used to form a jet where the inner phase 
was jetting inside the middle phase. 
 
The formulation screening process was started with PLGA (85:15, Mw = 50,00070,000) 
in the middle phase and PVA (Mw =13,000-23,000, 8789 % hydrolyzed) in the inner and 
in the outer phase (Table 3). The viscosities of the phases were attempted to adjust to 
correspond with each other by gradually reducing the quantity of PLGA in the middle 
phase.  
 
 
Table 3. Formulations 14 of PLGA and PVA.  
# Outer phase Middle phase Inner phase 
Formulation 1 
 
5 % PVA in water 
 
0.1 % PLGA in DCM 
 
5 % PVA in water 
 
Formulation 2 
 
5 % PVA in water 
 
0.02 % PLGA in DCM 
 
5% PVA in water 
 
Formulation 3 
 
5 % PVA in water 
 
0.01 % PLGA in DCM 
 
5% PVA in water 
 
Formulation 4 
 
5 % PVA in water 
 
0.005 % PLGA in DCM 
 
5% PVA in water 
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The PLGA used above was then changed to another PLGA (50:50; Mw = 50,00065,000, 
Polyscience Inc., U.S.) (Table 4). The concentration similar to PLGA of 85:15 was tested 
and the viscosity of the outer and inner phases, first were increased, then the viscosity of 
the inner phase decreased, and finally, attempted to stabilize with PEG 6000 (Mw = 
5,0007,000, Sigma-Aldrich, Germany).  
 
 
Table 4. Formulations #513 of PLGA and PVA.  
# Outer phase Middle phase Inner phase 
Formulation 5 
 
5 % PVA in water 
 
0.06 % PLGA in DCM 
 
5 % PVA in water 
 
Formulation 6 
 
5 % PVA in water 
 
0.03 % PLGA in DCM 
 
5 % PVA in water 
 
Formulation 7 
 
10 % PVA in water 
 
0.06 % PLGA in DCM 
 
10 % PVA in water 
 
Formulation 8 
 
10 % PVA in water 
 
0.03 % PLGA in DCM 
 
10 % PVA in water 
 
Formulation 9 
 
10 % PVA in water 
 
0.03 % PLGA in DCM 
 
2 % PVA in water 
 
Formulation 10  
 
10 % PVA in water 
 
0.03 % PLGA in DCM 
 
0.5 % PVA in water 
 
Formulation 11 
 
10 % PVA in water 
 
0.03 % PLGA in DCM 
 
only water 
 
Formulation 12 
 
10 % PVA in water 
 
0.014 % PLGA in DCM 
 
only water 
 
Formulation 13 
 
10 % PVA in water 
 
0.014 % PLGA in DCM 
 
10 % PVA and PEG 
(1:4) in water 
 
Alternative polymers were tested for the outer and the inner phases (Table 5). PLGA 
concentrations in the inner phase were kept minimal and the effect of Tween
®
 20 (Sigma-
Aldrich, U.S) in the outer phase was also tested. PCL (Mw = 70,00090,000, Sigma-
Aldrich, U.S.), which is soluble in nontoxic ethyl acetate (Sigma-Aldrich, U.S.), was tested 
as an alternative polymer in the middle phase. The viscosity of the inner phase was kept 
minimal by not adding polymers.  
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Table 5. Formulations #1417 containing Tween and PCL as alternative polymers.  
# Outer phase Middle phase Inner phase 
Formulation 14 
 
0.1 % Tween 20 in 
water 
0.014 % PLGA in DCM 
 
10 % PVA and PEG 
(1:4) in water 
Formulation 15 
 
0.1 % Tween 20 in 
water 
0.014 % PLGA in DCM 
 
only water 
 
Formulation 16 
 
10 % PVA in water 
 
2 % PCL in DCM 
 
only water 
 
Formulation 17 
 
10 % PVA in water 
 
2 % PCL in ethyl acetate 
 
only water 
 
 
Finally, PLA (Polysciences Ins., U.S.) was chosen for the polymer of the middle phase 
(Table 6). A slight increase of the viscosity for the inner phase was also tested.  
 
 
Table 6. Formulations #18–20 containing PLA. 
# Outer phase Middle phase Inner phase 
Formulation 18 
 
10 % PVA in water 
 
5 % PLA in DCM 
 
only water 
 
Formulation 19 
 
10 % PVA in water 
 
5 % PLA in DCM 
 
1 % PVA in water 
 
Formulation 20 
 
10 % PVA in water 
 
5 % PLA in DCM 
 
0,5 % PVA in water 
 
 
 
6.2.2   Double emulsion with combining microfluidics and bulk method 
 
The most simple microfluidic production of droplets is the one with tip glass capillary 
device producing single emulsion droplets using flow-focusing (Figure 16). Droplet 
production was easy to achieve and it was constant despite the slight changes in the flows. 
To obtain double emulsion droplets this system was connected to the outer phase outside 
the microfluidic system. The single emulsion droplets were collected to a vial containing 
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the outer phase and mixed there with a magnetic stirring in order to form double emulsion 
droplets.  
 
 
 
Figure 16. One tip glass capillary device for formation of single emulsion (W/O). The 
device consists of: two inlets for the inner phase (a) and two for the outer phase (b); the 
hydrophobic tip (c); and the outlet for the droplets (d).  
 
 
Single emulsion droplets were rather easily formed with a wider range of flow rates 
(Figure 17). The flow rates in the oil phase were 3,00020,000 µL/h and 1002,000 µL/h 
in the water phase. The process started with higher flow rates and they were adjusted so 
that the interphase was formed at the tip of the collection capillary. 
 
 
 
 
Figure 17. Flows of the phases in one of the tip glass capillary device for single emulsion 
(W/O). Phases flow in the square capillary and form an interphase at the tip of the 
collection tube. Single emulsion droplets form from the innerphase as they move through 
jetting to dripping transition at the beginning of the collection capillary.   
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Formulation screening for this method was started with lower concentrations, more similar 
to the bulk formulations found in the literature (Tomar et al. 2011; Coccoli et al. 2008) 
(Table 7). PCL was used in the inner phase and the concentrations varied in order to form 
stable W/O emulsions. Before mixing with the outer phase the stability of the W/O 
droplets was followed. Also, PLGA and PLA (W/O) single emulsions were tested, but the 
droplets were not stable due to the fast evaporation of DCM. Out of three polymers, PCL 
was the only one that dissolved in ethyl acetate. Dissolution of PCL was accelerated by 
heating ethyl acetate to 40 °C and stirred for 1 hour.  
 
Table 7. Formulations #21–23 of PCL with low concentrations of PVA. 
# Outer phase Middle phase Inner phase 
Formulation 21 
 
0.5 % PVA in water 
 
3 % PCL in ethyl acetate 
 
0.5 % PVA in water 
 
Formulation 22 
 
0.5 % PVA in water 
 
1.7 % PCL in ethyl acetate 
 
0.5 % PVA in water 
 
Formulation 23 
 
1 % PVA in water 
 
3 % PCL in ethyl acetate 
 
0.5 % PVA in water 
 
 
The quantities of PVA in the outer and in the inner phase were increased to stabilize the 
droplets (Table 8). The PVA concentrations of the outer phase were adjusted so that the 
mixing rate, and thus, the droplet formation, was ideal. The inner and middle phases were 
adjusted optimally for stability and flow in the microfluidic device. Finally, the fluorescent 
agent FITC-dextran (Mw = 10,000, Molecular Probes, U.S.) was added to the inner phase 
for the confocal studies for the particles. Particles prepared with the combination method 
were also collected, washed and dried. 
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Table 8. Formulations #24–28 of PVA and PCL. 
# Outer phase Middle phase Inner phase 
Formulation 24 
 
1 % PVA in water 
 
3 % PCL in ethyl acetate 
 
5 % PVA in water 
 
Formulation 25 
 
10 % PVA in water 
 
3 % PCL in ethyl acetate 
 
1 % PVA in water 
 
Formulation 26 
 
5 % PVA in water 
 
3 % PCL in ethyl acetate 
 
1 % PVA in water 
 
Formulation 27 
 
1 % PVA in water 
 
3 % PCL in ethyl acetate 
 
1 % PVA in water 
 
Formulation 28 
 
1 % PVA in water 
 
3 % PCL in ethyl acetate 
 
1 % PVA in water 
and FITC dextran 
 
Alternatively, also Tween 20 was tested and the effect on the particle size was evaluated 
(Table 9). Two different concentrations were tested.  
 
Table 9. Formulations #29 and 30 of Tween, PCL and PVA. 
# Outer phase Middle phase Inner phase 
Formulation 29 
 
1 % Tween 20 in water 
 
3 % PCL in ethyl acetate 
 
1 % PVA in water 
 
Formulation 30 
 
10 % Tween 20 in water 
 
3 % PCL in ethyl acetate 
 
1 % PVA in water 
 
 
 
6.2.3   Double emulsion with biphasic flow 
 
In the glass capillary devices with biphasic flow, the inner and middle phase flow is the 
same cylindrical capillary (Figure 18). An extra cylindrical capillary is placed in the 
cylindrical capillary for the middle phase. This capillary is stretched using a flame. The 
inner phase flowed through this capillary into the middle phase forming water drops in the 
middle phase. 
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Figure 18. Glass capillary device for biphasic flow: (a) inlet for the inner phase; (b) inlet 
for the middle phase; (c) inlet for the outer phase; (d) hydrophobic and hydrophilic tips of 
100 and 150 µm, respectively, with the latter being the collection tube; (e) closed inlet; and 
(f) outlet for the droplets.  
 
In this device it was essential that the cylindrical glass capillary for the inner and the 
middle phase was well coated hydrophobic in order to prevent the inner and the middle 
phase from reversing and forming oil drops in water, instead of forming water drops in oil 
as desired. As the water drops surrounded with oil reached the tip, double emulsion 
droplets with ultrathin shells were formed (Figure 19). With the biphasic flow range of 
flow rates used was smaller. The inner and middle phases flowed always at the same rate 
of 1500, 1000 or 500 µL/h. The flow rate of the outer phase was either 3000 or 2500 µL/h.  
 
 
Figure 19. Flows of the phases in the glass capillary device for biphasic flow for double 
emulsion droplets (W/O/W). The inner and middle phases’ flow in the first cylindrical 
capillary. Stretched capillary is inserted into the cylindrical capillary and the inner phase 
flows through it, forming water phase droplets into the oil phase. This forms droplets with 
ultrathin shells as they move to the collection capillary and interact with the outer phase 
flowing from the square capillary.  
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In between the water droplets, the leftover oil formed O/W single emulsion droplets. 
Double emulsion droplets were separated from the single emulsion droplets as they were 
collected into the vial with collection media (NaCl in water). Double emulsion droplets 
sink into the bottom of the vial and single emulsion droplets, with only ethyl acetate inside, 
float to the surface of the collection media due to their lower density. The osmolarity of the 
collection media corresponded to the osmolarity of the inner phase. The osmolarity of the 
inner phase was studied as described earlier.  
 
Formulation screening for this device design started with PLA in DCM and was continued 
with PCL in the middle phase (Table 10). DCM was not suitable for the glass capillary 
device with biphasic flow, and thus, PCL was the only ethyl acetate soluble polymer used 
in these formulations. The viscosity of the inner phase was kept high in order to co-flow 
with the viscose middle phase.  
 
Table 10. Formulations #31–33 of PVA, PLA and PCL.  
# 
Outer phase Middle phase Inner phase 
Formulation 31 
 
10 % PVA in water 
 
5 % PLA in DCM 
 
10 % PVA and PEG 
6000 (1:4) in water 
Formulation 32 
 
10 % PVA in water 
 
5 % PCL in ethyl acetate 
 
10 % PVA and PEG 
6000 (1:4) in water 
Formulation 33 
 
5 % PVA in water 
 
2.5 % PCL in ethyl acetate 
 
10 % PVA and PEG 
6000 (1:4) in water 
 
Concentrations of polymers were further adjusted and optimized for stable particle 
production. Two fluorescent agents were used: hydrophilic FITC-dextran (Mw = 10,000, 
Molecular Probes, U.S.) for the inner phase and hydrophobic 3,4,9,10-perylene-
tetracarboxylic dianhydride (Sigma-Aldrich, China) for the middle phase (Table 11). The 
fluorescent agents were chosen so that the excitation-emission spectra did not overlap. 
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Table 11. Formulations #3438 of PVA, PLA and PCL. Final optimization of the 
concentrations and formulations with fluorescent agents.  
# Outer phase Middle phase Inner phase 
Formulation 34 
  
5 % PVA in water 
 
3 % PCL in ethyl acetate 
 
10 % PVA and PEG (1:4) 
in water 
Formulation 35 
 
5 % PVA in water 
 
5 % PCL in ethyl acetate 
 
10 % PVA and PEG (1:4) 
in water 
Formulation 36 
 
10 % PVA in water 
 
3 % PCL in ethyl acetate 
 
10 % PVA and PEG (1:4) 
in water 
Formulation 37 
 
5 % PVA in water 
 
3 % PCL in ethyl acetate 
 
10 % PVA and PEG (1:4)  
and FITC-dextran in water 
Formulation 38 
 
5 % PVA in water 
 
3 % PCL in ethyl acetate 
and perylene 
10 % PVA and PEG (1:4)  
and FITC-dextran in water 
 
Particle loading was done first with a model protein β-galactosidase (from Aspergillus 
oryzae, Sigma-Aldrich, Japan) (Table 12). Due to the dextrin used to stabilize the protein, 
the water solubility was low, and thus, changes in the inner phase were attempted.  
 
Table 12. Formulations #3942 of PVA and PCL loaded with β-galactosidase.  
# Outer phase Middle phase Inner phase 
Formulation 39 
  
5 % PVA in water 
 
3 % PCL in ethyl acetate 
 
0.5 % PVA and 5 %  
β-galactosidase in PBS 
Formulation 40 
 
5 % PVA in water 
 
3 % PCL in ethyl acetate 
 
1.5 % PVA and PEG 
(1:2) and 5 % β-gal in PBS 
Formulation 41 
 
5 % PVA in water 
 
3 % PCL in ethyl acetate 
 
10 % PVA and PEG (1:4) 
and 0.4 % β-gal in water 
Formulation 42 
 
5 % PVA in water 
 
3 % PCL in ethyl acetate 
 
10 % PVA and PEG (1:4), 
0.4 % β-gal in water 
 
The properties of the inner phase were further determined with rheology tests. Rheological 
measurements were performed for the inner phases of formulations #37, 38 and 39. The 
instrument used for the rheology measurements was Ares-G2 Rheometer (TA Instruments 
Inc., U.S.). Ares G2 was chosen for this experiment, since it had separate motor and 
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transducer, and thus, enables measuring stress independently of the applied shear 
deformation. Two parallel measurements of 3 min for each sample were conducted. 
Optimization of the inner phase was continued and the phase further developed by 
increasing the quantity of PVA and PEG (Table 13).   
 
Table 13. Formulation #43 and 44 for increasing the viscosity of the inner phase.  
# Outer phase Middle phase Inner phase 
Formulation 43 
 
5 % PVA in water 
 
3 % PCL in ethyl acetate 
 
20 % PVA and PEG (1:4) 
in water 
Formulation 44 
 
5 % PVA in water 
 
3 % PCL in ethyl acetate 
 
20 % PVA and PEG (1:4) 
and FITC-dextran in water 
 
Finally, the inner phase with 20 % PVA and PEG was loaded with 2.5 % of salbutamol 
sulphate (Alfa Aesar, U.S.) and 1 % of bovine serum albumin (Sigma-Aldrich, Germany) 
(Table 14).   
 
Table 14. Formulations #45 and 46 loaded with salbutamol sulphate and bovine serum 
albumin.  
# Outer phase Middle phase Inner phase 
Formulation 45 
 
5 % PVA in water 
 
3 % PCL in ethyl acetate 
 
20 % PVA and PEG (1:4)  
2.5 % salbutamol in water 
Formulation 46 
 
5 % PVA in water 
 
3 % PCL in ethyl acetate 
 
20 % PVA and PEG (1:4) 
1 % BSA in water 
 
Drying of the particles was also attempted. However, a suitable drying method was not 
found and only very small quantities of the particles were dried.  
 
Double emulsion (W/O/W) with only bulk method was prepared as a reference. The 
emulsion consisted of 10 % PVA and PEG (1:4) and 0.4 % (w/w) β-galactosidase in the 
inner phase, 3 % PCL in ethyl acetate in the inner phase and 5 % PVA in the outer phase. 
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The emulsion was produced with sonication (Ultrasonic processor, Ace Glass, U.S.). The 
quantities of the phases were in the ratio 1:10:100.  
 
6.3   Characterization of the microspheres 
 
6.3.1   Particle size 
 
The particle size was determined by optical microscopy and diameter measurements. 
Diameter measurements were done with Image J software for scientific image analysis 
(National Institutes of Health, U.S.) and measured according to 1 mm scale for the optical 
microscope. The average diameter and standard deviation were also calculated. The 
Student’s t-test was conducted to compare the batches, and thus, possible significant 
statistical differences evaluated.  
 
The particle size was measured from the collected particles of 5 batches of formulations 
containing 5 % PVA in the outer phase, 3 % PCL in the middle phase and either 10 or 20 % 
of PVA and PEG (1:4) in the inner phase (formulations #34, 37, 42 and 43; n = 100). As a 
reference, also the particle size of the droplets prepared with bulk method was determined 
(n = 100). 
 
In addition, the particle size during the microfluidic preparation process was determined 
(formulations #37 and 42; n = 100) and compared with the collected particles from 
corresponding batches. Also, the particles sizes of a small batch of dried particles were 
measured.  
 
The shell thickness of two batches of the particles during the preparation process (n = 100) 
and after collection (n = 100) was measured from the formulation #38 as described above. 
The shell thickness was determined with optical microscope (Leica, Germany) during the 
preparation process and with confocal microscope (Leica Microsystems CMS GmbH, 
Germany) from the collected particles. The ratio of the shell thickness and diameter of the 
whole particle was determined and evaluated.  
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6.3.2   Number of successful double emulsion droplets 
 
One of the parameters that determined whether an emulsification process was working 
properly is the number of successful double emulsion droplets. The number of droplets 
containing the inner phase was determined with confocal microscope (Leica Microsystems 
CMS GmbH, Germany). The content of the droplets was examined from 3 batches of 
formulation #37, where the inner phase was made fluorescent with FITC-dextran (Mw = 
10,000, Molecular Probes, U.S.; n = 200). The percentage of droplets containing the inner 
phase was calculated. As a reference, double emulsion with bulk method was prepared 
with FITC-dextran in the inner phase and the number of successful double emulsion 
droplets was calculated (n = 200).  
 
6.3.3   Short time stability 
 
Short time stability studies were conducted observing variation in the particle sizes with 
optical microscopy and Image J software as described above (6.3.1). Particles were 
measured (n = 100) and the Student’s t-test used to evaluate whether the variation was 
statistically significant. Batches for the short time stability tests were stored in a 
refrigerator at 8 °C. 
 
Three batches (formulations #34 and 41) were monitored for 4 weeks and the samples were 
taken when the time elapsed was 0, 1, 3, 7, 14, 21 and 28 days (with exception to earlier 
the third small batch n = 50, other two n = 100). Two batches (formulations #34 and 37) 
were monitored for 6 weeks and the samples were taken when the time elapsed was 0, 28, 
35 and 42 days. The batch size was the main limiting factor for monitoring the stability at 
longer times or more frequently. For reference, the stability of bulk emulsion droplet was 
monitored and the samples were taken when the time elapsed was 0, 1 and 3 days. In 
addition, the stability of the dried particles was also monitored from a small batch for 28 
days.  
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6.3.4   Surface properties of the particles 
 
Topographical properties of the particles were studied with SEM microscope (Carl Zeiss 
AG, EVO 55 Environmental SEM, Germany), as shown in Figure 20. EVO series was 
chosen because it has a wet stage system that allowed taking pictures of the sample in 
liquid without the need of coating, freeze-drying or preparing the sample in any method. 
With polymer microspheres the coating easily damages the particle surface and influences 
the quality of the results. The wet stage method was the most suitable for small particle 
batches and the original state of the outer shell was preserved. With this method the 
chamber is cooled down using liquid nitrogen as also in other SEM methods. The main 
difference was that the conditions in the chamber were set to maintain water vapour in the 
chamber. The vapour present in the chamber made obtaining the images possible.  
 
 
Figure 20. (a) EVO 55 Environmental SEM microscope, and (b) chamber and the wet 
stage.  
 
The sample used was the particles with 0.4 % loading of β-galactosidase. The sample was 
placed on a paper platform in the collection media with a pipette. The chamber was cooled 
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with liquid nitrogen to water vapor state and the electric beam was run through upper and 
lower aperture of 100 and 500 µm.  
 
6.3.5   Encapsulation efficiency 
 
The encapsulation efficiency was determined for PCL particles loaded with 0.4 % β-
galactosidase, 2.5 % salbutamol and 1 % BSA (formulations #42, 45 and 46). Samples 
were taken from the supernatant of 3 different batches of each formulation. Samples of 1 
mL were taken immediately after the droplet preparation process was completed. Batches 
of formulation #44 containing 2.5 % of salbutamol were additionally sonicated in an 
ultrasound bath (Fritsch, Ultrasonic-cleaner, Laborette 17, Germany) for 3 h to determine 
the total quantity of salbutamol released. Samples were taken immediately after the 
sonication.  
 
Samples of β-galactosidase were analyzed with modified activity assay (altered Sigma-
Aldrich protocol). 0.1 mL of the sample was added to the ONPG solution and the mixed 
solution was allowed to react at 37 °C for 10 min. After that the reaction was stopped with 
0.3 mL of 5 M NaCO3 solution. The protein activity was determined by absorbance of the 
reaction product of ONPG at 420 nm (showing a yellow color), with an accepted 
absorbance being between 0.2 and 0.5. The instrument used for the absorbance 
determination was Nanodrop spectrophotometer (ND-1000, U.S.). A standard curve for the 
activity assays of β-galactosidase solutions in water with concentrations from 10 to 500 
µg/mL was made (R
2
 = 0.981). 
 
Samples of salbutamol and BSA were analyzed with high performance liquid 
chromatography (HPLC Thermo System Products, Agilent 1200 Infinity Series, Agilent 
Technologies, Germany). The HPLC salbutamol method was developed using a 
Discovery
®
 C18 column (Supelco Analytical, U.S.), flow rate of 1 mL/min with a mobile 
phase consisting of methanol and PBS (25 mM; pH 3) at a ratio of 25:75 (v/v) operating at 
25 °C. The running time was 4 min and the UV detection of salbutamol was set at 270 nm 
with a retention time of 2.6 min. A standard curve for the salbutamol quantification at 
concentrations from 0.5 to 25 µg/mL was made (R
2
 = 0.99988). The BSA method was 
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developed using a Vydac 214MS C4 column (Grace Davison Discovery Science, U.S.), 
suitable for protein analysis, flow rate of 1 mL/min with a mobile phase consisting of ACN 
and 0.1 % TFA operating at 40 °C. The protein analysis required a gradient of TFA and 
ACN of ratios of 80:20 (v/v) to 35:65 (v/v) within 12 min and reversing back to 80:20 (v/v) 
within 8 minutes, with a total run time of 20 min. The UV detection of BSA was set at 210 
nm with a retention time of 8.5 min. A standard curve for BSA quantification from 
concentrations of 5 to 500 µg/mL in NaCl corresponding to the collection media was made 
(R
2
 = 0.99991). BSA method was adapted for Agilent 1200 combining three BSA methods 
found in literature (Umrethia et al. 2010). 
 
The encapsulation efficiencies were calculated from the HPCL results using Equations 10 
and 11. The encapsulation efficiency for salbutamol was determined by comparing the 
total quantity of salbutamol with the quantity of salbutamol in the supernatant. The 
experimental total quantities of salbutamol were compared with the theoretical total 
quantities of salbutamol. 
 
      
                                                                 
                            
                    (10) 
 
The encapsulation efficiency of BSA was calculated based on the theoretical total 
quantities of BSA. These theoretical quantities were determined by calculation in amount 
of BSA in the inner phase used to prepare droplet for each experiment. The experimental 
quantities were not obtained, since the sonication process would have led to degradation of 
the protein structure.  
 
      
                                                 
                    
                         (11) 
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6.3.6   Drug release 
 
Drug release from the particles was evaluated with confocal microscopy and dissolution 
tests. With confocal the follow-up of one PCL particle was observed for 2 h. The confocal 
observation begun as the time elapsed from the beginning of particle preparation process 
was 0.5 h and the additional images were taken with time points of 1, 1.5 and 2 h. 
 
Drug release from the particles was evaluated with dissolution tests using diffusion cells 
(Snapwell diffusion chambers, Grown Glass Company Inc., U.S.) and the release tests 
were made in glass containers. Additionally the release of FITC-dextran was observed with 
confocal microscope. Both dissolution tests were conducted with two dissolution media: a 
PBS at pH 7.2 and a HCl buffer at pH 1.2. Samples used were PCL particles (formulation 
#46) loaded with 1 % of BSA and pure BSA powder was used as reference.  
Snapwell diffusion chambers consisted of inner and outer chambers: outer chambers to 
control the temperature and inner chambers to serve as donor (3 mL) and receiver (1 mL) 
compartments (Figure 21). The outer chambers were connected to a pump and the water 
heater system with silicone tubes. The water heater and pump system kept the water 
running through the system with constant temperature of 37 °C during the experiment. 
Small stirring magnets were placed in the bottom of the donor and receiver compartments 
to stir the samples. Silicone rings were used in between the chambers to prevent them from 
leaking or breaking. Between the silicone rings cellulose ester membrane (Spectra/Por 
Biotech CE Membranes, Spectrum Labs, U.S.) with MWCO of 100,000 or 1,000,000 Da 
was used. 
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Figure 21. Diffusion cell device and Snapwell diffusion chambers (Grown Glass Company 
Inc., U.S.). 
 
The particles were placed in the donor compartment and the aliquots were taken from the 
receiver compartment with a Finnpipette when the elapsed time was 0, 10, and 30 min, and 
1, 2, 3, 4, 5, 6, 24 and 48 h. At 48 h an aliquot from the donor compartment was also taken 
in order to evaluate the diffusion through the membrane during the experiment. Each 
aliquot taken was 0.5 mL and the same volume of fresh media was replaced back in order 
to keep the volume of the dissolution constant.  
 
Drug release tests (Figure 22) in glass containers were conducted on heating and stirring 
plates (H+P Labortechnik AG, Multitherm, Germany). The volume of the releasing media 
was 20 mL. The temperature was monitored during the dissolution tests and kept at 37°C ± 
0.5 °C. Each aliquot taken was 1 mL and the same volume of fresh media was replaced 
back in order to keep the volume of the dissolution constant. Aliquots were taken when the 
elapsed time was 30 sec, 1, 2, 3, 4, 5, 10, and 30 min, 1, 2, 3, 4, 5, 6, 24, and 48 h, 1 and 2 
weeks. More aliquots were taken in the beginning of the dissolution test, since the effect of 
the membrane was not present in this experiment. After 2 weeks the glass containers with 
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the dissolution test system were sonicated (Sonics Vibra-cell, Sonics and Materials Inc., 
U.S.) in order to release the total amount of BSA remaining in the particles.  
 
 
 
Figure 22. Drug release tests in glass containers on stirrer and heating plates (H+P 
Labortechnik AG, Multitherm, Germany). 
 
 
The aliquots taken were analyzed with HPLC for BSA as described in section 6.3.5. 
Standard curves for the quantification of BSA from concentrations of 5 to 500 µg/mL at 
pH 7.2 (R
2
 = 0.99992) and pH 1.2 (R
2
 = 0.99965) were made. The results were processed 
so that the quantity of the drug in the samples was cumulatively added to the total quantity 
of released drug, which was then compared to the total quantity of the drug in the aliquot to 
obtain the quantity of the released drug as a percentage (Equation 12).  
 
 
      
                     
                                    
                                                                (12) 
 
Where C is the concentration of BSA in the aliquot multiplied with the total quantity of 
media, added to the cumulative quantities (m0, m1, mn) of previous aliquots divided by the 
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difference between the total quantity of BSA used in the particle preparation process and 
the total quantity of BSA in the supernatant. 
 
 
7.   RESULTS AND DISCUSSION 
 
7.1   Microfluidic devices and production of droplets 
 
Successful droplet production was dependent on the device and formulation used. 
Formulations that could be used to produce double emulsion droplets in bulk, would 
generally not work with microfluidics. The common ratio of phases in W/O/W emulsion 
was around 1:10:100 (Jeong et al. 2003) to 1:25:100 (Coccoli et al. 2008). In microfluidics 
the ratios varied according to the device design used and were determined directly by the 
flow rates. The production rate was also dependent on the flow rates. Overall, the 
production using one glass capillary device was slow and for actual industrial scale 
production scaling-up would be necessary.  
 
Microfluidic devices were hand-made, and thus, the design was not always identical. 
Additionally, all of the devices could not be considered fit for droplet production. When 
producing droplets with polymers in organic solvents as the middle phase each device 
could only be used once. Due to this, variation between the batches was more significant. 
If PDMS devices would have been used in these experiments, the structure of the devices 
would have been identical and there would not have been differences caused by the device 
structure in the batches.  
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7.2    Formulation screening study 
 
7.2.1 Double emulsion with two tip glass capillary devices 
 
The two tips of glass capillary devices were the most challenging design out of the three 
device designs used in these experiments. Formulations #14 with PLGA (85:15) were not 
successful. With higher concentrations of PLGA droplet formation could not be achieved. 
With the extremely low concentration of 0.005 % of PLGA single emulsion droplets were 
formed. However, even the single emulsion droplets were not stable. The higher portion of 
lactic acid with the PLGA was, the more viscous middle phases were formed (Wu 1995). 
Thus, the formulations #513 PLGA (85:15) were replaced with PLGA (50:50) where the 
portion of glycolic acid was smaller.  
 
The formulations #5 and 6 produced single emulsion droplets. With these formulations the 
inner phase jetting within the middle phase was possible, but jetting to dripping transition 
was not achieved. The viscosities of the inner and the outer phase were increased in 
formulations #7 and 8, but this failed to solve the issue. In formulations #911 the polymer 
content of the inner phase was decreased, but the inner phase contained any quantity of 
protein, double emulsion droplet production was not possible. 
 
With the formulations #1113 the content of the inner phase was further altered. As the 
inner phase contained only water, partial double emulsion droplet formation was possible. 
Partial success rate was approximately from every third to every seventh droplet being 
double emulsion droplet and the droplets formed in between being single emulsion droplets. 
Perfect double emulsion droplet production was not achieved. In formulations #14 and 15 
the PVA in the outer phase was replaced with Tween 20, but it did not stabilize the 
droplets nearly as well as PVA. In the formulations #16 and 17, PLGA was replaced with 
PCL, but either the solvent used was DCM or ethyl acetate, the middle phase turned out to 
be even more viscose than with PLGA, and thus, the droplet production was impossible. 
 
Neither PLGA (85:15), PLGA (50:50) nor PCL was suitable for droplet production in the 
two tip glass capillary device due to the excessive viscosity in the middle phase. Thus, 
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PLGA was replaced with PLA (intrinsic viscosity from 0.50.65 to 0.2) that would form 
less viscous middle phase.  
 
With the formulation #18 successful double emulsion droplet production was 
accomplished (Figure 23). However, the inner phase contained only water, and thus, the 
particles were not stable and collapsed at the end of the collection tube. For more stable 
droplets the PVA content of the inner phase was increased (formulations #19 and 20); as 
the viscosity of the inner phase increased the droplet production was not achieved.  
 
 
 
Figure 23. Optical microscope image showing the successful production of double 
emulsion droplets with the two tip glass capillary device.  
 
The droplet production with the two tip glass capillary device had various problems 
(Figure 24). For example, the production process was often disrupted because of these 
issues and had to be started from the beginning. Due to these issues with the two tip glass 
capillary devices no constant droplet production was achieved.  
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Figure 24. Optical microscope images showing the problems with double emulsion droplet 
production: (a) viscosity, (b) air bubbles, (c) clogging, (d) formation of single emulsion 
droplets, (e) formation of droplet with multiple cores, and (f) breaking of the interphase.  
 
The viscosity of the middle phase often led to formation of uneven interphase. The more 
viscous the middle was the easier it formed along the square capillary, forming two 
streams instead of one. The impact of viscosity is more significant in microscale due the 
low Reynold’s number (Squires and Quake 2005), and thus, the behavior of the phases 
could not be controlled with the changes of the flow in order to overcome the effect of 
viscosity.  
 
The preparations taken before the preparation process, washing the device and filtering the 
phases in some cases failed to prevent clogging or air bubbles in the device. Clogging was 
caused mostly by the polymers precipitating in the phases, especially in the middle phase 
were the polymers used were soluble only in organic solvents and the solubility to even 
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those was limited. Clogging was more likely to take place as the polymer concentrations in 
the phases were higher. The statistic probability of clogging could be reduced with heating 
and stirring of the middle phase during the production process. However, the temperature 
should be carefully controlled in order to keep the overall temperature of the emulsion 
under 42 °C to protect the protein from degradation. Changes in the temperature would 
also affect the viscosity of the middle phase and the flow rates should be adjusted carefully 
for changing the process variables. The viscosity of the phases was also the main cause for 
air bubbles in the capillary system. The bubbles were more persistent and tended to form 
easier in the more viscous phases. With the two tip glass capillary devices air bubbles 
disturbed the interphase and the droplet production ceased. In most cases the air bubble 
could be removed from the tip area with high flow rates. However, the procedure required 
beginning the flow rate adjustment and droplet production process from the starting.  
 
A common phenomenon with the two tip glass capillary devices was single emulsion 
droplet (O/W) production or double emulsion droplet production (W/O/W) with multiple 
cores. Single emulsion droplets were formed when the inner phase would not reach the 
interphase at the tip with correct flow rate. Droplets with multiple cores were produces as 
the flow rate of the inner phase was higher. The double emulsion droplets with multiple 
cores were not stable and collapsed in the beginning of the collection tube. In some cases, 
the interphase would breakdown from the side of the middle phase. This was yet a 
viscosity issue and required restarting the production process again. 
 
The two tip glass capillary devices themselves worked with different formulations, such as 
polymersome formulations with glucose in water in the middle phase PEG-b-PLA in 
chloroform and toluene, and PVA in water in the outer phase (Duncanson et al. 2012b). 
With this formulation the viscosity of the inner phase is close to the viscosity of water and 
the middle phase is less viscous, yet not suitable for drug formulations. Also, the droplets 
have been stabilized with hydrogels to ensure more stable production and droplets (Kim et 
al. 2013). These droplets contained 15 or 10 % (w/w) of poly(ethylene glycol)diacrylate 
(PEGDA) in water as the inner phase, 5 % (w/w) of PEG-b-PLA in chloroform and hexane 
(38:62) and 10% (w/w) of PVA in the outer phase. Adding 0.2% (w/w) of photoinitiator in 
the inner phase polymerizing the droplets was possible. This made the inner phase more 
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rigid, and thus, the droplets remained intact. The two tip glass capillary devices have also 
been used to produce multiple emulsions with phases that have viscosities better suitable 
for the application (Kim and Weitz 2011).  
 
In this study, for example, triple emulsion droplets (O/W/O/W) were prepared using water 
as the inner phase, hexadecane and 1% (w/w) Span 80 in the first oil phase, 3% (w/w) 
PVA and 1% (w/w) F108 in water in the second water phase, and finally hexadecane and 1% 
(w/w) Span 80 as the outer phase. Another sort of polymersomes were created with 10% 
(w/w) of PVA in water as the outer phase, PEG-b-PLA and PLA in a mixture of 
chloroform and hexane (38:62%, v/v) as the middle phase, and as the formulation was 
designed for protein expression bacterial ribosomal extract (E. coli) and MreB DNA 
plasmid in water as the inner phase (Martino et al. 2012). Also, in this study the 
chloroform residues in the product would be challenging in medicinal product, yet the co-
polymer in these organic solvent enabled the droplet formation.   
 
However the desired formulation for protein drug encapsulation in this study contained 
only one polymer (PLGA, PLA or PCL) in the middle phase making it highly viscous, and 
thus, the two tip glass capillary devices could not be considered for producing of these 
particles. The two tip glass capillary devices required more complicated, and thus, 
significantly more expensive formulations. Scaling-up of a process with no guarantee of 
functioning would be highly unprofitable. Thus, the technology for droplet production was 
changed to more practical alternatives, such as combining microfluidics with bulk method 
and biphasic flow. 
 
7.2.2 Double emulsion with combining microfluidics and bulk method 
 
Single emulsion droplet production with one tip glass capillary devices proved to be a 
simpler droplet production method than the method using the two tip glass capillary 
devices. Droplets with microfluidics were chosen to produce with PCL in ethyl acetate due 
to the stability of W/O emulsion. This made also the manufacturing process possible 
outside of a fume hood since ethyl acetate is nontoxic (Ramalakshmi and Raghavan 1999). 
The formulations #2123 contained very moderate quantities of polymers, especially in the 
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inner and in the outer phases. As the viscosities failed to match between the phases, very 
unstable droplets were produced with microfluidics and the lack of PVA working as a 
surfactant in the outer phase prevented the formation of stable droplets.  
 
In formulations #2426 the polymer concentrations were increased significantly. Double 
emulsion droplet formation was achieved and the formed droplets were even possible to 
collect and dry. In the formulation #24 the inner phase contained 5% (w/w) PVA in order 
to stabilize the particles. The increase of PVA quantity failed to do so and instead the size 
of the W/O droplets increased, and the single emulsion particles became less stable. Thus, 
1% (w/w) of PVA in the inner phase proved to be the ideal concentration. With the 
formulations #25 and 26 where PVA concentrations of 5% (w/w) and 10% (w/w) were 
tested, the more viscous outer phase slowed down the droplet formation and prevented the 
ethyl acetate from evaporating, thus creating large and slightly unstable droplet. The ideal 
formulation for the combination technique was the formulation #27 with 1% (w/w) of PVA 
in the inner and in the outer phase. The maximum concentration for PCL in ethyl acetate 
was 3% (w/w) due to solubility and viscosity issues.  
 
Spherical particles were formed when the polymer worked as a surfactant in the outer 
phase was PVA. In the formulations #29 and 30 when Tween 20 was tested in the outer 
phase the system failed to produce spherical droplets or encapsulate the first emulsion into 
double emulsion in the outer phase. The spherical particles from the formulation #27 were 
polydispersed and part of the droplet population lacked the inner phase. This was caused 
by the lack of control with the latter emulsification process (Figure 25).  
 
59 
 
 
Figure 25. Schematic of the droplet formation with the combination method. As the first 
emulsion (W/O) is mixed to the outer phase the double emulsion droplets form, and thus, 
the variation in the particle size and content is significantly heterogeneous.   
 
The particle formation was fast and drying of the particles was possible with filter paper. 
The dried particles preserved their spherical forms. This simple method was successful in 
the drying of the combination method particles due to the size and PCL quantities in the 
particles.  
 
The sole advantage of combining bulk method with microfluidics was the preservation of 
the protein structure with mild emulsification technique for the first emulsion in the 
process. However, the double emulsion droplet production was not as sophisticated as in 
the methods that produces double emulsion droplets directly. All the advantages of 
microfluidics were not exploited and the double emulsion droplet formation process was 
not controlled nor could it have been monitored with the fast cameras. Also, similar issues 
with clogging and air bubbles as described earlier emerged with the one tip glass capillary 
devices. 
 
With microfluidics various formulations for single emulsion droplet manufacturing have 
been developed. With these glass capillary devices, O/W single emulsion droplets were 
produced. Extremely monodisperse droplets were produced with polyfluorene (PFO) in 
toluene as the inner phase and PVA in water as the outer phase (Kuehne and Weitz 2011). 
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The particle size was controlled by adjusting the concentrations. Also, PLGA and PLA 
were possible to formulate as a single emulsion (O/W) (Duncanson et al. 2012c). In this 
droplet formation process the outer water phase contained 10% (w/w) of PVA and the 
inner phase varying concentrations of PLA and PLGA. Similar particles with 5% (w/w) of 
PVA in the outer phase and 5% (w/w) of PLA in the inner phase were prepared 
(Vladisavljević et al. 2012). The single emulsion droplets were stable and monodisperse. 
 
However, even though these formulations were often meant as templates for drug delivery, 
loading them with water soluble drugs is self-evidently impossible and would require 
changing the system into double emulsion droplet production. This again would set new 
requirements for the formulations. Also, DCM and toluene are toxic and especially toluene 
is unsuitable for drug formulations.  
 
7.2.3 Double emulsion with biphasic flow 
 
With the biphasic flow droplet production from more viscous phases was possible, since an 
interphase is not formed in the square capillary, and thus, minor changes in the flows of the 
phases did not disturb the droplet production on a larger scale. In addition, since the 
interphases formed within the first cylindrical capillary the flow in the square capillary 
affected only the dripping to jetting transition, and thus, also the flow rates needed lesser 
changes to achieve the droplet production process than in the other devices designs used in 
this study.  
 
When the process was successful all of the water drops formed double emulsion (W/OW) 
drops (Figure 26). The flow rates were adjusted to low speeds (500–1000 µL/h) as the 
biphasic flow was formed in the first cylindrical capillary. Once started and undisrupted 
the droplet formation was stable and continuous for several hours.  
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Figure 26. Optical microscope images showing the droplet formation with biphasic flow: 
(a) oil phase reaching the tip of the first capillary, (b) oil droplets (O/W) forming, (c) 
beginning of the formation of double emulsion (W/O/W) droplets, and (d) continuing of 
the droplet formation from the water drop.   
 
Within the process a change in the size of the water drops in the first cylindrical capillary 
was observed. The water particles started smaller and gained more size during the 
preparation process. This was caused by the wearing out of the hydrophobic coating in the 
first cylindrical capillary.  
 
The collection of the droplets was made possible by the density differences with the single 
emulsion droplets and double emulsion droplets. When the oil phase was stained with Nile 
red, it was possible to observe the separation and formation of the droplets (Figure 27).  
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Figure 27. Collection and separation of the droplets from the biphasic flow. Bigger oil 
droplets floated and the smaller double emulsion droplets with less of the pink dye sank in 
the bottom of the collection vial.  
 
As the molarity of the collection media was set according to the molarities of the inner 
phases of formulations #34 and 43, 50 mM with 10% (w/w) PVA:PEG 6000 and 156 mM 
with 20% (w/w) PVA:PEG 6000. The molarities did not change as the small quantities of 
fluorescent agents or model drugs were added to these inner phases.  
 
The formulation screening for the biphasic flow began with the formulation #31: 5% (w/w) 
PCL in the middle phase with DCM as the organic solvent. DCM was not suitable solvent 
for this system, since caused PVA to precipitate in the first cylindrical capillary. Due to 
this, neither PLA nor PLGA were suitable options for the polymer in the middle phase, as 
they failed to dissolve in ethyl acetate. The obvious choice within the three polymers used 
in the study was PCL. Additionally, ethyl acetate was a non-toxic option for the middle 
phase and since it is used mainly in pharmaceutical industry (Dutia 2004), and also in food 
industry to decaffeinate tea and coffee (Ramalakshmi and Raghavan 1999).  
 
In the formulation #32 the polymer in the ethyl acetate middle phase was PCL with 
concentration of 5% (w/w). The 5% concentration for PCL in ethyl acetate was too high in 
terms of solubility. The middle phase was too viscose and impossible to handle within the 
droplet preparation process. For the formulation #33, the PCL concentration was reduced 
to 2.5% (w/w) with decreasing the quantity of PVA in the outer phase to match the 
viscosities and droplet production was possible.  
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The contents of the phases were further adjusted in the formulations #3436. 3% (w/w) 
proved to be the maximum concentration for PCL. Optimal droplet production was 
achieved with 5% (w/w) of PVA in the outer phase and 10% (w/w) PVA and PEG 6000 
(1:4) in the inner phase. The formulation development was continued with successfully 
adding fluorescent FITC-dextran to the inner phase and perylene to the middle phase. The 
results from observing the droplets with confocal microscopes are discussed later in section 
7.3.2. 
 
Drug loading to the formulations started with β-galactosidase as a model protein. The inner 
phase was altered in the formulations #39 and 40 due to the poor water-solubility of β-
galactosidase. Poor water-solubility was caused by dextrin chain used as a preservative in 
the β-galactosidase (Sigma-Aldrich, U.S.). The quantity of β-galactosidase was increased 
to 5% (w/w) as the quantities of the polymers decreased. These formulations failed to 
produce double emulsion droplets and as a result the polymer content of the inner phase 
was reversed to the 10% (w/w) of PVA and PEG 6000 (1:4), and the maximum amount of 
β-galactosidase possible to dissolve to that interphase was determined to be 0.4% (w/w). 
With the therapeutic proteins used as medicines, the protein are usually so potent that for 
the desired effect already very small quantities are sufficient. The dosage is dependent on 
the protein drug used. For example, the therapeutic dosage for insulin is 10 ng/mL (Van 
den Berghe et al. 2003) and for botulinum toxine 10 µg/mL (Borodic et al. 1994). 
 
The effect of the content of the inner phase was further determined by the viscosity 
observations (see Appendix 1). The results of the rheology measurements conducted for 
the inner phases of the formulations #3941 are presented in Figure 28. The significant 
data in Figure 28 is between 100 and 130 seconds when the viscosity measurement 
process has settled down. It is possible to determine that the viscosity of the inner phase of 
the formulation #39 is 4 times the viscosity of the other two inner phases. This explains 
why the droplet production was only successful with the formulation #39. The dynamic 
viscosities of the formulations #40 and 41 were almost corresponded to the viscosity of 
water. This affected the droplet formation process so that it failed to succeed.  
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Figure 28. The viscosities of three different inner phases. Two parallel measurements with 
Ares G2 were conducted. The viscosity is expressed as dynamic viscosity, Pascal seconds 
(Pa   s). 
 
The results from these experiments were used to adjust the content of the inner phase. The 
drug loading had to be kept small due to the necessary polymer content in the inner phase. 
In the β-galactosidase preparation the protein was stored with dextrin. These dextrin chains 
decreased the solubility of the β-galactosidase preparation. In case of more pure 
preparation of the protein higher drug loadings could have been achieved.  
 
The formulation development was continued with adding PVA and PEG to the inner phase 
to the concentration of 20% (w/w) and increase in the polymer quantity in the inner phase, 
facilitating slightly the droplet preparation process. The droplet produced with the 
formulations containing 20% (w/w) (formulations #43–46) were otherwise identical to the 
droplets containing 10% (w/w) of PVA and PEG (formulations #34–38, 41, and 42). The 
formulation with 20% (w/w) was chosen for further development and the loading with 
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FITC-dextran was successful. The model protein was changed to BSA due to the problems 
observed with β-galactosidase, such as the water-solubility, purity and analysis. BSA 
loading with 1% (w/w) was possible and constant droplet production was achieved. 1% 
(w/w) loading for a protein drug was already quite acceptable. Other model drug, 
salbutamol sulphate was used with 2.5% (w/w) loading. Due to the small size and excellent 
solubility to water, salbutamol performed excellently as a model drug.  
 
Overall, the double emulsion droplet production with the biphasic flow was successful and 
the production rates were decent enough to prepare the necessary quantities of the droplets 
to further characterization. Nonetheless, problems common to the microfluidic droplet 
production were present also in the devices designed with biphasic flow. Main problems 
with the devices were alignment mistakes. Problems with the droplet production were 
similar to the issues discussed earlier. The main problem was the clogging of the 
capillaries. Additionally, the problems discussed earlier (Figure 24) also affected the 
success rate of droplet formation in biphasic flow. 
 
Specific problems in the biphasic flow were diameter of the additional cylindrical capillary 
for the inner phase and disruption of the double emulsion droplet production in the middle 
of the water drop movement to the collection capillary. The additional cylindrical capillary 
was made with stretching the capillary in a flame. Due to this method variations in the 
shape were significant and resulted in either too small water droplets that could not be 
considered as successful biphasic flow, or a jet of the inner phase, which failed to reach 
droplet production. Disruption with the water drop took place when the oil phase did not 
distribute evenly along the wall of the first cylindrical capillary, and thus, the double 
emulsion droplet formation ceased (Figure 29). Thus, the inner and outer phases mixed 
and small single emulsion droplets were formed from the middle phase. This phenomenon 
is the main reason for the leaking of the model drug from the double emulsion particles 
decreasing the encapsulation efficiencies achieved.  
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Figure 29. Optical microscope images showing the disruption in droplet formation with 
biphasic flow: (a) normal production of double emulsion droplets with thin shells, and (b) 
breaks and droplet forming are single emulsion droplets from the oil phase.  
 
Drying of the particles failed to succeed. Even though various filters were used the process 
did not provide decent quantities of dried particles. Drying attempts indicated that the 
particles were adhesive. The dried particles also flocculated as preserved (see section 
7.3.3).  
 
Other formulations for the biphasic flow have been developed (Kim et al. 2011). The 
droplets produced with 25% (w/w) PEG6000 in the inner phase, 1% (w/w) of Span 80 in 
the middle phase and 10% PVA in the outer phase. The droplets produced in this study 
were more successful (see section 7.3.2). However, 25% (w/w) of PEG in the inner phase 
would have inhibited loading the inner phase with any quantity of protein drug. In the same 
study the double emulsion droplets with biphasic flow were also manufactured from 10% 
(w/w) PVA in water as the inner phase, 20% (w/w) PLA in toluene as the middle phase 
and 3% (w/w) PVA in the outer phase. The double emulsion droplet preparation with these 
compounds was successful, yet toluene as the organic solvent in the middle phase is an 
immediate backset for employing this formulation to actual medical preparations. Biphasic 
flow has also been used for manufacturing of liposomes, giant lipid vesicles and Janus 
liposomes with different lipid in outer and in the inner part of the bilayer (Arriaga, L., 
personal communication, SEAS, January 2013). 
 
Even though the formulations developed with PCL produced continuously stable double 
emulsion droplets, the formulation could be further improved with diversifying the 
components in the phases. The formulation for the biphasic flow of this study could be 
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further improved, for example, with UV polymerization (Kim et al. 2013) or co-polymers 
(Duncanson et al. 2012d).  
 
7.3   Characterization of the microspheres 
 
7.3.1 Particle size 
 
Particles from the formulations #34 and 43 as well as the loaded particles with the same 
phase components were fairly monodisperse and spherical (Figure 30). Particle 
observation and diameter determination using optical microscopy was successful.  
 
 
Figure 30. PCL particles observed with an optical microscope.  
 
The particle sizes with standard deviations of the 5 batches observed are presented in 
Table 15. All the batches were found not to be significantly different using the Student’s t-
test analyses. Due to the variance within the batches they could all be considered to be 
similar.  
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Table 15. Particle sizes of 5 different batches collected and observed with optical 
microscope. Batches 1 and 2 are particles of formulation #34, batch 3 is of formulation #37, 
batch 4 is of formulation #42, and batch 5 is of formulation #43.  
 Batch 1 Batch 2 Batch 3 Batch 4 Batch 5 Average 
Particle size (µm) 47 23 35 37 41 36 
Standard deviation (±µm) 6 8 6 5 7 6 
 
According to the Student’s t-tests performed, statistically significant differences could be 
found in the particle sizes between all the batches observed. The standard deviation was 
not as significant as with particles prepared with bulk methods, and thus, error bars of the 
particle populations did not overlap and statistical differences were observed with the 
Student’s t-tests. 
 
ImageJ software was also used to determine the particle sizes (see Appendix 2), since the 
program defines the diameter extremely precisely, and thus, the standard deviating was 
more significant than it would have been, if the particles sizes were determined in a less 
accurate method. Overall, optical microscopy was not the most convenient tool for 
determining the particle sizes. The samples observed were limited to small quantities of 
particles that did not necessarily represent the size distribution of the whole batch. 
Alternative methods for determining the particle size could be considered to produce 
results with better quality, for example, with Coulter counter (Gee and Bauder 1986) or 
light blocking methods (Gibbs 1982). All the batches were manufactured with different 
glass capillary devices, and thus, the particles produced were not identical. This issue could 
be overcome by using PDMS devices and ensuring standard conditions for the droplet 
production. 
 
Additionally, significant differences in the particle sizes were observed when the particle 
size during the preparation process was compared with the size of the collected particles. 
Particles were larger when prepared. The process particle size was 6 times the size of the 
collected particles as the average diameter of the particles during the process was 218 ± 39 
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µm and it decreased to 36 ± 6 µm, which was the average diameter of the collected 
particles.  
  
As the diameter of the particles decreased the shell thickened. The shell of the collected 
particles was 3.3 times thicker than the shell of the particles during the preparation process. 
The average shell thickness was 2.1 ± 0.7 µm during the particle preparation process. The 
shell thickened to 7.0 ± 2.0 µm as the particles were collected. The change in the particle 
size and in the shell thickness could not be explained by the differences in osmotic 
pressure (Figure 31). The flow according to the osmolarity of the phases should have been 
from outside into the particles. However, the particles shrank and lost part of their water 
content.  
 
 
Figure 31. Schematics of the (a) water flow caused by the differences in osmotic pressure 
and (b) the actual change in the particle size.  
 
The shrinking of the particles was caused by crystallization of the PCL in the middle phase. 
As the PCL crystallizes, the PCL units were drawn closer together and the water is pushed 
out of the particle. As a result, as the size of the inner sphere decreases, the shell thickens 
as observed when comparing the process particles size and the size of the collected 
particles with optical microscope. The crystallization was driven by van der Waals forces 
between the PCL units. The existence of these forces was determined by the molecular 
structure of PCL. 
 
Also, the particle sizes of the combination method and the bulk method were determined 
successfully. The size of the particles produced with the combination method was 155 ± 86 
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µm. The standard deviation was more significant than with the microfluidics methods, 
which directly produced the double emulsion droplets. Also, the particle size was 
significantly bigger in the case of bulk method. The main reason for abandoning this 
technique was that the particle size was large and is not suitable for drug administration. 
Generally, the microparticles for oral drug delivery should preferable have diameters of 
less than 100 µm (Freiberg, Zhu 2004).  Smaller particles could have been created with 
greater input of energy to the system. However, increasing the stirring rate was not an 
option, since particles only formed with low stirring rates. 
 
The size of the particles produced with the bulk method was 30 ± 20 µm. With sonication 
it was possible to produce smaller particles. However, sonication is likely to destroy the 
protein structure and also the encapsulation efficiency is likely to be poorer. Manufacturing 
double emulsion droplets with biphasic flow proves thus to be more sophisticated droplet 
preparation methods than the other methods within this research. 
 
Comparing the results discussed earlier with other studies on PCL microparticles showed 
that in many studies the microparticles manufactured were smaller in size. Microparticles 
with diameter of 2 µm have been successfully prepared (Somavarapu et al. 2005). In some 
studies microparticles with more similar sizes were also achieved. For example, particles 
with diameter ranging from 21.3 to 40.8 µm with quite similar deviation have been 
produced with the solvent evaporation method (Jeong et al. 2003). Also, larger PCL 
particles for drug administration have been developed. Particles with diameters ranging 
from 70 to 80 µm have been designed for controlled release of warfarin (Scala-Bertola et al. 
2012), and from 61 to 190 µm for the delivery of quercetin (Natarajan et al. 2011). Various 
sizes of PCL particles have been produced and particles regardless their accurate size can 
be used in different medical applications. 
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7.3.2 Number of successful double emulsion droplets 
 
Microfluidic droplet preparation proved to be sophisticated enough to produce double 
emulsion droplets with 100% success rate. All the droplets produced and collected were 
double emulsion droplets that contained the inner phase. Confocal fluorescence 
microscopy enabled observing the presence of the inner phase (Figure 32). 
 
 
Figure 32. Confocal fluorescence microscopy images of PCL particles with FITC-dextran 
(green) and β-galactosidase in the inner phase. 
 
Moreover, the presence of the middle phase was also observed under confocal fluorescence 
microscopy (Figure 33). With the correct dyes the inner phase and the middle phase were 
clearly distinguished in the confocal images. Observing the dyed phases separately was 
also possible, since the excitation/emission spectra did not overlap. All the particles 
consisted of the inner and the middle phase, the shells were evenly distributed along the 
inner sphere and particles were fairly monodisperse.  
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Figure 33. Confocal fluorescence microscopy images of PCL particles with FITC-dextran 
(green) in the inner phase and perylene (red) in the middle phase.  
 
The particles produced with biphasic flow were compared to the particles produced with 
the combination technique (Figure 34). Apart from being significantly larger, all the 
combination method particles did not contain the inner phase. Additionally, based on 
confocal fluorescence microscope observations, the combination method particles seemed 
to contain varying concentrations of the inner phase. The lack of control in the double 
emulsion formation process may explain this phenomenon. Also, small quantities of FITC-
dextran were observed in the media indicating poor encapsulation efficiency.  
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Figure 34. Confocal fluorescence microscopy images of PCL particles with biphasic flow 
(a), and with combination method (b). The scale bars of the images are significantly 
different: particles in image (b) are 5 times larger than in image (a).  
 
The observation of the bulk emulsions with confocal fluorescence microscope was 
challenging (Figure 35). Due to the very poor encapsulation efficiency and less clear 
separation of the particles, the content of single droplet was difficult to observe. However, 
it was possible to determine that larger quantity of FITC-dextran was not encapsulated 
within the particles and that the size distribution and variation in the FITC-dextran 
concentration within the particles was more significant. 
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Figure 35. Confocal fluorescence microscopy images of particles of the bulk emulsion 
batch prepared as a reference with FITC-dextran (red) in the inner phase. 
 
Overall, the particles prepared with microfluidics were more successful as double emulsion 
droplets. This accuracy achieved in the particles content enabled more precise dosing of 
microencapsulated drugs. When it comes to, for example, therapeutic proteins the dosages 
have to be precise and double emulsion droplets prepared with bulk technique are not able 
to provide such precision. The aspect of polymer particle content has been somewhat 
overlooked in the literature, since the processes used could not be controlled to affect the 
success rate of the particles in this level.  
 
7.3.3 Short time stability 
 
Short time stability tests indicated that the particles were stable up to 4 weeks. The 
particles of all the batches kept their appearance similar during the follow-up (Figure 36). 
The quantity of particles in the images varied according to the sample taken from the 
batches. Generally, the samples were kept small due to the limited quantities of the batches.  
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Figure 36. Optical microscope images showing the particles of formulation #34, batch 1 in 
the short-time stability tests on days (a) 0, (b) 1, (c) 3, (d) 7, (e) 14, (f) 21, and (g) 28. 
Differences in color are due to the settings of the optical microscope.  
 
Figure 37 elucidates the changes in the particle sizes with the standard deviations. The 
batches observed were significantly different from each other, and thus, the changes in the 
particle sizes were compared only within each batch using Student’s t-test to determine the 
statistically significant differences.  
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Figure 37 Particle sizes on days 0, 1, 3, 7, 14, 21 and 28. Batches 1 and 2 are particles of 
formulation #34 and batch 3 contains particles of formulation # 37. Standard deviations are 
presented as error bars of the 100 particles measured. 
 
Statistical analyses using the Student’s t-tests conducted to the follow-up batches until day 
28 showed the following results. In batch 1, statistically significant differences in the 
particle sizes occurred between all days except days 0 and 1, as well as between days 3 and 
7. With batch 2 the particle size did not change between days 21 and 28. The statistically 
significant differences in the particle sizes for the third batch were found to be between 
days 0 and 1, days 1 and 3, days 3 and 7, as well as between days 7 and 14. 
 
The short time stability tests were successfully conducted for 6 weeks for two new batches. 
In addition to measuring the particle size, the collapsing of the particles was observed in 
these samples (Figure 38).  
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Figure 38. Optical microscope images showing the particles of formulation #34 on days (a) 
28, (b) 35 and (c) 42 (Batch 1).  
 
The size of the collapsed particles did not increase and the collapsed particles remained 
round but flat. Particle sizes of these microspheres are presented in Figure 39. The two 
bathes observed were significantly different in size.  
 
 
Figure 39 Particle sizes of formulations #34 (Batch 1) and #37 (Batch 2) on days 0, 28, 35 
and 42. Standard deviations are presented as error bars of the 100 particles measured. 
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According to the Student’s t-test results within batch significant changes in the particle size 
took place between days 0 and 1, and days 28 and 35. No statistically significant 
differences were found between days 35 and 42. With batch 2, statistically significant 
differences were found in between the particle sizes of days 0 and 28, days 28 and 35, as 
well as between days 35 and 42.  
 
Results for the collapsing of the particles during the short time stability study are presented 
in Table 16. With these batches collapsed particles were detected already on day 28. The 
collapsing rate between the batches varied. 
 
Table 16. Percentages of collapsed particles on days 28, 35 and 42. 
Collapsed particles (%) Day 0 Day 28 Day 35 Day 42 
Batch 1  0 5.7 18.3 41.0 
Batch 2 0 0.7 15.0 18.9 
Average ± standard 
deviation 
0 3.2 ± 3.5 16.6 ± 2.3 30.0 ± 15.6 
 
In many cases all the particles prepared were used in the stability tests. This affected the 
remaining population and the sample left to be examined the following time. Additionally, 
other problems with optical microscopy discussed earlier (see section 7.3.1) also affected 
the results of the stability study.  
 
Particle sizes in the bulk emulsion were observed for 3 days (Figure 40). The particles in 
the bulk emulsion were significantly less stable than the particles prepared with 
microfluidic technology.  
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Figure 40. Particle sizes in the bulk emulsion for the days 0, 1 and 3. Standard deviations 
are presented as error bars of the 100 particles measured.  
 
Deviation in the particle size was significantly greater and the particles were more 
polydispersed than particles produced with microfluidics. The bulk particles collapsed 
faster than the particles manufactured with microfluidics. On day 0 ca. 2.9% of the 
particles were collapsed, on day 1 ca. 24.5% and on day 3 ca. 27.8%. The collapsing rate 
of 27.8% on third day indicated that the bulk particles were significantly more unstable 
than the particles prepared with microfluidics. This indicated that the formulation for the 
bulk droplet production was not ideal and it proved that the particles prepared with 
microfluidics were significantly more stable.  
 
Particles were stable also when dried (Figure 41). Dried particles tended to stick together 
and form flocculates. The dried particles stayed intact and spherical up to 28 days, and 
altogether appeared to be more stable than the particles stored in the collection media.  
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Figure 41. Optical microscope images showing the dried PCL particles: (a) after drying 
(day 0) and (b) after 4 weeks (day 28). 
 
Stability of the polymer microspheres has been monitored in various methods. Stability 
studies in stressed conditions and short-time stability studies are conducted as for other 
drug formulations. Particle size follow-up was not commonly chosen. The collapse of PCL 
particles at 4 weeks was observed, for example, using SEM, and the percentage of 
collapsed particles was not determined (Cheng et al. 2010).  
 
7.3.4 Surface properties of the particles 
 
Particles appear to have a non-porous, smooth surface and monodisperse size (Figure 42). 
Evaluation of the surface properties of the particles without coating was made using a wet 
stage EVO 55 SEM microscope. 
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Figure 42. SEM images of PCL particles: (a) is a 506  magnification taken at chamber 
pressure of 682 Pa with 26 kV, and (b) is a 735  magnification of different particles of the 
same batch with the same pressure and voltage.   
 
The resolution of the images taken with wet stage was limited and more accurate images 
were impossible to obtain. Wet stage imaging containing water vapour in the chamber did 
not provide clearest images. However, the obtained images were clear enough to determine 
the previously described properties of the particles. The accuracy of the background 
provided good comparison for the particle surfaces. The paper used as the background was 
shown highly detailed, and thus, it is possible to conclude that since the particle surface did 
not have such structure, it was flawless. Particle size determined from the SEM images did 
not statistically differ from the results of optical microscopy. The batch observed was the 
first batch used in the 4-week stability test. 
 
PCL particles prepared in other studies also showed non-porous surfaces and altogether 
similar surface properties from PCL and poly(ε-caprolactone) (Tomar et al. 2011; 
Somavarapu et al. 2005; Bolzinger et al. 2007; Hnaien et al. 2011; Lee et al. 2000). 
 
7.3.5 Encapsulation efficiency 
 
Encapsulation efficiency determination for β-galactosidase failed to succeed. Ethyl acetate 
residue in the samples effected the degradation of ONPG, thus given erroneous results and 
causing problems with reproducibility. Loading particles as well as further experiments 
with β-galactosidase were not conducted due the difficulties with analysis.  
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Encapsulation efficiencies for salbutamol sulphate and BSA were determined successfully 
and the results were remarkable. The results of the tests were reproducible and the 
variation between the parallel tests was extremely moderate. Encapsulation efficiencies of 
salbutamol sulphate are presented in Table 17. 
 
Table 17. Encapsulation efficiencies (EEs) of salbutamol. 
 1 2 3 Average 
EE (%) 86.5 80.5 82.5 83.2 
 
Theoretically, 100% encapsulation efficiency could be achieved with microfluidics, since 
the particles do not lose their content when stored and the leaking of the inner phase only 
took place as the double emulsion droplet production was disturbed as described in section 
7.2.3 As the PCL particles containing salbutamol were broken with sonication, it was 
possible to determine the absolute amount of salbutamol encapsulated in the whole system. 
As these quantities were compared with the theoretical quantities, some differences were 
found (Table 18). 
 
Table 18. Theoretical and experimental determination of the amount of salbutamol 
encapsulate in the particles.  
 1 2 3 
Theoretical amount of 
salbutamol (µg) 
25.0 12.5 25.0 
Experimental amount of 
salbutamol (µg) 
20.4 15.7 28.5 
Difference between 
results (µg) 
4.6     (82 %) 3.2       (126 %) 3.5     (114 %) 
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Differences between the theoretical and the experimental amounts of the encapsulated 
salbutamol were caused by the variation in the drop size in the first cylindrical capillary 
during the preparation process. During most processes the drop size grew as the 
preparation process was continued. Thus, the batches collected in the beginning of the 
process were most likely to contain less of the inner phase than theoretically assumed. The 
batches collected towards the end of the process were most likely to contain more of the 
inner phase than theoretically assumed. This size variation can be explained by the 
hydrophobic coating slowly wearing off, and thus, the inner diameter of the cylindrical 
capillary growing and allowing larger drops to form.  
 
The total amounts of BSA were only determined theoretically (Table 19). This creates a 
moderate error source for the encapsulation efficiency of BSA. However, the fact that the 
BSA batches used in encapsulation efficiency experiments were selected so that the 
variation of the drop size during the droplet preparation process was as marginal as 
possible, and should have decreased the effect of this source of error.  
 
Table 19. Encapsulation efficiencies (EEs) of BSA. 
 1 2 3 Average 
EE (%) 72.2 92.4 87.3 84.7 
 
The encapsulation efficiency measured from the PCL particles either with salbutamol 
sulphate or BSA produced using microfluidic technology were substantially higher than 
the encapsulation efficiencies achieved with conventional double emulsion production 
methods.  
 
Generally, the PCL particles made with microfluidics were significantly better in terms of 
encapsulation efficiency than the particles prepared by other methods found in the 
literature. In many studies the encapsulation efficiencies that were achieved were 
approximately 40–60% (Somavarapu et al. 2005; Coccoli et al. 2008). Other studies 
indicated poorer encapsulation efficiency of barely 40% (Scala-Bertola et al. 2012, 
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Bolzinger et al. 2007, Jeong, Lee and Cho 2003, Hnaien et al. 2011). In some other studies, 
relatively high encapsulation efficiency have been achieved for big particles; these 
particles had diameters larger than 180 µm, and thus, were not suitable for oral 
administration (Natarajan et al. 2011). Generally, an encapsulation efficiency of 70% was 
considered high, with flow-focused jetting cell PCL particles with encapsulation efficiency 
of 42–79% was achieved (Cheng et al. 2010). 
 
7.3.6 Drug release 
 
Confocal fluorescence microscopy 
 
Figure 43 illustrates the release of FITC-dextran from a single PCL particle. The particle 
was followed for 2 h during the experimental released of its content.  
 
 
Figure 43. Confocal fluorescence microscope follow-up images of one PCL particle, 
showing the release of its FITC-dextran (green) content: (a) the shell rupturing from the 
thinnest spot, (b) particle losing its FITC-content, (c) and (d) particle without FITC-dextran 
content.  
 
All the particles did not release their content simultaneously. The particle observed with 
confocal fluorescence microscopy had an uneven shell that wore off quicker that the shells 
of the other particles and enabled the follow-up when the FITC-dextran was still 
undoubtedly fluorescent. The degradation of the PCL particles, which was an 
autocatalyzed reaction (Pitt 1990), occurred in the shell evenly, and thus, the thinnest part 
of the shell broke first. After the shell broke down, the FITC-dextran content released 
within 1.5 h. The release kinetics observed this way proved that the droplet did not lose all 
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its content at once and the dissolution happened gradually and in a somewhat controlled 
manner. Additionally, the droplet did not collapse as the content of the inner phase was 
released. The PCL shell remained intact and the particle kept its spherical form.  
 
Nevertheless, the confocal fluorescence microscopy follow-up required approximately 30 
min of usage of the laser on the same particle. This could have decreased the excitation 
from the fluorescent FITC-dextran, and thus, made the particle followed dimmer than it 
actually was. In addition, this also made the release process appear faster than it is in 
reality.  
 
Dissolution tests 
 
Dissolution tests performed in the Snapwell diffusion chambers failed to succeed. Even 
though the membranes chosen had presumably low protein binding and pore size 
significantly greater than the molecular size of the protein, the membranes hindered the 
diffusion process so that the results represent rather the quality of the membrane than the 
actual drug release.  
 
The release tests performed in the glass vials were successful and produced more accurate 
data on the dissolution process. Physiological BSA dissolved immediately into the 
dissolution media. BSA was dissolved completely when the time elapsed was 1 min. At   
30 s 58% of BSA at pH 7.2 and 19% of BSA at pH 1.2 was dissolved. More acidic 
conditions retarded slightly the dissolution of BSA. The protein solubility is often 
dependent on the pH of the dissolution media (Pelegrine and Gasparetto 2005). 
 
The release of BSA from the PCL particles at pH 7.2 is presented in Figure 44 and Figure 
45. The results of the tests are presented up to one week, since after that the protein 
degradation began (see Appendix 3).  
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Figure 44. Release profiles of physiological BSA and BSA released from PCL particles at 
pH 7.2 during one week.  
 
 
 
Figure 45. Release profiles of physiological BSA and BSA released from PCL particles at 
pH 7.2 during the first48 hours of the experiment. 
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Protein degradation may have begun within hours of starting the experiment. Thus, a larger 
error in the results is possible. The variation between the results of the two parallel tests 
was moderate. The shrinking of the particles most likely caused the slow and uncomplete 
release of BSA. If the particle shell had not thickened, the erosion of shell caused by the 
autocatalyzed degradation of PCL would have been faster the shell and thus the rate and 
degree of release would have changed.  
 
The release of BSA from the PCL particles at pH 1.2 is presented in Figure 46 and Figure 
47. At lower pH the degradation of BSA began earlier and affected the results more 
significantly. However, also at lower pH, part of the BSA was released immediately and 
after that the release rate slowed down. The concentration of BSA started to drop after the 
elapsed time was 5 h. After this point the results at pH 1.2 are not valid.  
 
The detection limit in the BSA method was 5 µg/mL; the quantities below this 
concentration were undetectable, and thus, the slight increases in the drug release were 
possibly undiscovered.  
 
 
Figure 46. Release profiles of physiological BSA and BSA released from PCL particles at 
pH 1.2 during one week. 
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Figure 47.  Release profiles of physiological BSA and BSA released from PCL particles at 
pH 1.2 during the first 48 hours of the experiment. 
 
Sonication in the end of the experiment did not produce valid results. By sonication the 
protein degradation was faster than the release of the protein from the particles. Thus, 
HPLC analysis resulted in lower concentrations the longer the sonication was continued. 
Complete release and analysis of BSA was not possible. Using salbutamol or other 
hydrophilic small molecule as model drug would have been more suitable for modeling the 
drug release kinetics from the PCL particles. However, release kinetics and effect of pH 
with protein and drug with smaller molecular size is not similar and the exact modeling of 
protein kinetics is not possible. To produce valid results the formulation used and the drug 
release experiment itself must be further developed. 
 
Problems concerning drug release have also been observed in other studies where the PCL 
particles have been prepared with various bulk methods. In these studies, the complete 
release of the drug from the PCL particles has been challenging. The release studies on 
warfarin showed similar kinetics than those obtained in this study (Scala-Bertola et al. 
2012). For example, from the PCL microparticles containing ibuprofen nanoparticles 
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inside within 24 h approximately 40% of drug was released (Sheikh Hassan et al. 2009), 
whereas 4565% of quercetin was released within 700 h (Natarajan et al. 2011).  
 
Protein drug release from various PCL particles has also been widely studied. Differences 
between the release profiles were caused by the formulation and preparation method used. 
With BSA approximately 35% was released from the PCL particles within 30 days 
(Coccoli et al. 2008). In this study, very similar results using sonication and stirring as the 
production method were obtained. Only 50% of myoglobin was released in 48 h (Hnaien et 
al. 2011). When studied with recombinant hepatitis B surface antigen PCL particles 
released 80% of their content in 165 days (Tomar et al. 2011). On the other hand, 
papaverin was released from the PCL particles up to 80% within 170 h (Jeong et al. 2003). 
About 90% of lysozyme was possible to release from PCL particles within 30 days (Cheng 
et al. 2010). The differences in the release profiles were caused by the formulation and 
preparation method used. However, like in the research found in the literature also in this 
master’s thesis work the release of protein drugs was generally slower than the release of 
small molecule drugs.  
 
 
8.   CONCLUSIONS  
 
In this study, two functional formulations were developed: 5 % poly(vinyl alcohol) in the 
outer phase, 3 % of polycaprolactone in the middle phase and either 10 % or 20 % of 
polyethylene glycol and poly(vinyl alcohol) (1:4) in the inner phase. Overall, in this 
research work the microfluidic technology was demonstrated to have great potential for 
droplet manufacturing for pharmaceutical applications and to create templates for protein 
drug delivery. However, formulation screening process indicated that finding suitable 
formulations for microfluidics is demanding. Formulations had to contain phases that were 
correspondent to each other in terms of viscosity and the formulations required prolonged 
the optimization processes.  
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Producing double emulsion droplets (W/O/W) with the two tip glass capillary device was 
impossible using biodegradable polymers in solvents acceptable for medical preparations. 
Combining microfluidics with bulk method did not provide advantages in the formulation 
production besides protecting the protein structure in the preparation process. Droplet 
production was possible with the highly viscous organic solvent using the glass capillary 
device with biphasic flow. Yet, also this formulation required precise adjustments in order 
to produce stable droplets. Once the formulation was optimized, constant droplet 
production was achieved and a stable droplet production system was established.  
 
The double emulsion droplets prepared were significantly better in all aspects examined 
than the droplets produced with bulk methods. Overall, the microfluidic approach made it 
possible to develop mild preparation suitable for protein structured drugs, gaining high 
protein encapsulation efficiency and forming stable, monodisperse, and non-porous 
particles. The particle size varied according to the device used and even more 
monodisperse particles could be produced with poly(dimethylsiloxane) (PDMS) devices. 
Encapsulation efficiency was the most remarkable feature of these particles. Conventional 
methods are not able to reach encapsulation efficiencies of 85 % for the same size scale of 
particles. 
 
The only major set-back in the otherwise functional formulations was the unpredicted 
shrinking of the particles that was caused by the crystallization of PCL and led to imperfect 
drug release. This phenomenon mostly likely takes place as any sort of PCL particles are 
prepared, yet only with microfluidics the preparation process is possible to monitor and 
compare with the actual product. This possibility to monitor particles during formation 
creates an opportunity to learn more on the polymer behavior in the microparticle 
preparation processes.  
 
Further research would be required to determine whether the particle size could be more 
precisely controlled by using poly(dimethylsiloxane) devices and co-polymers, and even 
try with more complex formulations. To obtain better dissolution profiles the formulation 
should be further optimized to control the shell thickness of the droplets. Industrial scaling-
up production is not possible with the glass capillary devices and it would need a matrix 
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for poly(dimethylsiloxane) devices develop for biphasic flow and overcoming the issues 
related to the droplet preparation process. Yet the controlled particle preparation method 
offers interesting insight for pharmaceutical industry and these carefully optimized dosage 
forms could be employed for example for developing personalized medications.  
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APPENDIX 1 
Rheology measurements 
Formulation #39 
 
Sweep - 1 
Step time Temperature Stress Shear rate Viscosity 
Normal stress 
coefficient 
s °C Pa 1/s Pa,s Pa,s² 
11.0008 25.778 3.31E-03 0.10002 0.033087 -29.2905 
22.04 25.774 2.52E-03 0.215471 0.011717 -12.1372 
33.0767 25.766 1.85E-03 0.46421 3.99E-03 -2.27341 
44.1118 25.766 6.67E-03 1.00017 6.66E-03 0.544877 
55.149 25.764 0.0119723 2.15482 5.56E-03 0.752949 
66.1982 25.747 0.0200477 4.64193 4.32E-03 0.288263 
77.2335 25.749 0.0387751 10.0014 3.88E-03 0.010961 
88.2685 25.744 0.0817472 21.5468 3.79E-03 -1.68E-03 
99.3018 25.735 0.17419 46.4214 3.75E-03 -9.50E-04 
110.337 25.732 0.370748 100.012 3.71E-03 -3.80E-04 
121.37 25.725 0.793482 215.47 3.68E-03 -2.02E-04 
132.405 25.717 1.72126 464.214 3.71E-03 -1.52E-04 
143.437 25.712 4.04191 1000.12 4.04E-03 -1.39E-04 
 
Sweep - 2 
Step time Temperature Stress Shear rate Viscosity 
Normal stress 
coefficient 
s °C Pa 1/s Pa,s Pa,s² 
11.0008 25.692 2.45E-03 0.100011 0.024459 1.32544 
20.04 25.688 2.32E-03 0.215471 0.010771 -5.29873 
33.0747 25.682 3.63E-03 0.464249 7.82E-03 -0.918536 
44.1118 25.68 5.97E-03 1.00021 5.97E-03 0.627181 
55.147 25.675 0.0122962 2.15483 5.71E-03 0.605617 
66.1982 25.673 0.0196101 4.64198 4.22E-03 0.197806 
77.2355 25.664 0.0382432 10.0012 3.82E-03 -2.12E-03 
88.2687 25.664 0.0807071 21.5467 3.75E-03 -3.45E-03 
99.3038 25.659 0.172504 46.4215 3.72E-03 -1.36E-03 
110.337 25.653 0.369332 100.012 3.69E-03 -4.60E-04 
121.372 25.654 0.794264 215.469 3.69E-03 -2.17E-04 
132.407 25.646 1.72454 464.215 3.72E-03 -1.53E-04 
143.439 25.634 4.03734 1000.12 4.04E-03 -1.38E-04 
 
 
 
     
 
 
Formulation #40 
 
Sweep - 1 
Step time Temperature Stress Shear rate Viscosity 
Normal stress 
coefficient 
s °C Pa 1/s Pa,s Pa,s² 
11.0007 26.258 2.01E-04 0.100012 2.01E-03 -31.6295 
22.0398 26.251 2.48E-04 0.215471 1.15E-03 -10.9731 
33.0745 26.255 2.91E-04 0.46427 6.26E-04 -3.17657 
44.1117 26.256 3.90E-04 1.00012 3.90E-04 -0.397196 
55.1468 26.253 2.30E-03 2.15484 1.07E-03 8.25E-03 
66.1982 26.248 3.41E-03 4.64201 7.35E-04 -8.78E-03 
77.2353 26.249 8.36E-03 10.0013 8.36E-04 -2.86E-03 
88.2685 26.247 0.0208056 21.5468 9.66E-04 -7.88E-04 
99.3037 26.242 0.0466936 46.4216 1.01E-03 -8.18E-04 
110.337 26.238 0.104813 100.012 1.05E-03 -3.32E-04 
121.372 26.231 0.234577 215.469 1.09E-03 -1.83E-04 
132.405 26.231 0.616363 464.215 1.33E-03 -1.47E-04 
143.438 26.222 1.85953 1000.12 1.86E-03 -1.37E-04 
 
Sweep - 2 
Step time Temperature Stress Shear rate Viscosity 
Normal stress 
coefficient 
s °C Pa 1/s Pa,s Pa,s² 
11.0008 26.293 8.37E-03 0.100014 0.083715 3.88889 
22.04 26.291 8.05E-03 0.215471 0.037344 -3.40971 
33.0747 26.291 8.54E-03 0.464246 0.018402 0.554676 
44.1118 26.286 9.42E-03 1.00024 9.42E-03 1.21059 
55.147 26.287 0.0114446 2.15476 5.31E-03 0.329788 
66.1982 26.282 0.0123715 4.64197 2.67E-03 0.0861939 
77.2335 26.283 0.016979 10.0013 1.70E-03 7.41E-03 
88.2687 26.284 0.0299864 21.5468 1.39E-03 2.00E-03 
99.3018 26.274 0.0554195 46.4215 1.19E-03 -1.79E-05 
110.337 26.276 0.11078 100.012 1.11E-03 -2.35E-04 
121.372 26.277 0.243573 215.469 1.13E-03 -1.56E-04 
132.408 26.269 0.630506 464.214 1.36E-03 -1.40E-04 
143.439 26.261 1.88094 1000.12 1.88E-03 -1.37E-04 
 
 
 
 
 
 
Formulation #41 
 
Sweep - 1 
Step time Temperature Stress Shear rate Viscosity 
Normal stress 
coefficient 
s °C Pa 1/s Pa,s Pa,s² 
11.0008 26.071 9.36E-04 0.100014 9.36E-03 131.662 
22.0398 26.071 -2.40E-04 0.215471 -1.12E-03 57.8368 
33.0767 26.072 7.98E-04 0.464209 1.72E-03 18.8248 
44.1118 26.071 1.64E-03 1.00015 1.64E-03 5.9929 
55.149 26.072 4.96E-04 2.15471 2.30E-04 1.46349 
66.1982 26.066 1.06E-03 4.64208 2.29E-04 0.245281 
77.2335 26.074 7.50E-03 10.0011 7.50E-04 0.0414677 
88.2685 26.072 0.019918 21.5469 9.24E-04 8.41E-03 
99.3018 26.069 0.0474268 46.4213 1.02E-03 1.35E-03 
110.337 26.113 0.106342 100.012 1.06E-03 1.80E-04 
121.37 26.068 0.243396 215.469 1.13E-03 -5.99E-05 
132.406 26.068 0.633757 464.215 1.37E-03 -1.17E-04 
143.437 26.113 1.87632 1000.12 1.88E-03 -1.27E-04 
 
Sweep - 2 
Step time Temperature Stress Shear rate Viscosity 
Normal stress 
coefficient 
s °C Pa 1/s Pa,s Pa,s² 
11.0008 26.036 -5.02E-03 0.100011 -0.050174 5.44401 
22.04 26.035 -5.03E-03 0.215471 -0.023352 2.91614 
33.0747 26.04 -4.53E-03 0.464252 -9.76E-03 1.78252 
44.1118 26.041 -3.18E-03 1.00017 -3.18E-03 0.665913 
55.147 26.046 -1.73E-03 2.15469 -8.02E-04 0.262554 
66.1982 26.049 -3.64E-04 4.64198 -7.84E-05 0.012364 
77.2353 26.056 5.91E-03 10.0013 5.91E-04 7.42E-03 
88.2685 26.058 0.0186672 21.5468 8.66E-04 -8.07E-04 
99.3038 26.058 0.0448827 46.4217 9.67E-04 -7.22E-04 
110.337 26.064 0.105838 100.012 1.06E-03 -3.09E-04 
121.372 26.068 0.242489 215.469 1.13E-03 -1.69E-04 
132.405 26.072 0.624784 464.214 1.35E-03 -1.40E-04 
143.439 26.071 1.84694 1000.12 1.85E-03 -1.30E-04 
 
 
 
 
 
APPENDIX 2 
Particle sizes 
Batch 1 Batch 2 Batch 3 Batch 4 Batch 5 
43.6752 14.1426 50.327 47.776 34.4088 
47.4786 21.5928 30.506 43.572 40.8132 
51.777 14.2956 33.588 30.828 35.2008 
44.82 28.0062 33.588 36.65 39.6432 
50.049 21.8052 34.554 33.127 17.0748 
49.3506 33.1272 45.155 31.252 52.272 
58.0878 21.87 36.076 36.44 45.5094 
44.82 36.8658 36.68 29.777 37.9008 
48.3138 23.9076 32.593 37.155 35.8758 
44.0208 28.0152 30.506 36.44 37.7118 
53.2836 21.492 31.809 32.626 41.6754 
45.8784 17.973 29.998 43.065 39.7764 
53.8146 35.5284 36.59 41.587 39.4848 
56.8512 26.1144 29.998 38.887 36.8784 
51.9318 21.5766 32.894 35.617 34.9992 
46.971 20.0142 32.727 42.963 34.8966 
19.8216 44.1558 32.626 39.364 42.1632 
42.4368 42.1308 29.63 35.586 38.7594 
47.4786 18.5598 33.292 39.807 42.687 
42.1632 19.6434 33.424 37.771 37.9008 
39.7764 19.2312 31.497 32.626 34.9992 
45.5094 18.0054 31.427 31.427 34.1766 
42.9372 21.6252 29.63 33.848 43.0398 
53.1324 16.5762 28.304 40.976 36.3924 
48.1662 19.1754 33.588 39.89 35.901 
49.977 21.2994 27.676 35.556 38.8728 
41.868 23.8266 30.828 29.998 38.9412 
43.4106 24.2442 35.339 37.303 13.131 
50.7726 16.1496 37.067 40.68 31.6926 
51.2946 19.5912 26.831 38.774 41.4828 
43.9794 17.1972 29.63 49.247 42.9372 
50.7726 18.2466 33.424 45.446 43.7364 
46.971 21.9294 30.947 37.771 37.9008 
54.927 15.0516 29.886 38.774 40.4856 
48.9528 24.2442 33.587 31.497 51.4674 
52.5276 37.1412 33.155 35.832 34.7688 
46.6668 43.9956 37.253 37.944 41.4198 
47.4786 19.4832 29.329 38.089 37.7118 
 
 
47.7036 36.4482 31.213 33.848 37.1898 
53.6652 26.9568 39.404 35.679 38.6892 
45.6066 27.756 30.769 36.68 34.1766 
41.8464 40.5432 31.454 29.219 54.927 
39.2148 27.585 40.42 25.316 38.205 
53.1 37.3104 31.497 40.301 48.1842 
44.7012 25.5096 35.786 37.712 41.868 
44.0802 16.7652 36.696 36.44 35.901 
43.1838 16.9254 29.117 38.433 38.8278 
39.3948 15.2136 30.68 35.121 41.868 
50.7726 30.9204 30.947 39.112 37.7118 
48.5334 17.559 42.621 37.771 42.1632 
43.6752 12.7944 30.023 35.863 43.533 
44.82 22.6044 33.832 34.586 28.845 
52.7472 29.9214 38.182 31.427 45.333 
46.5714 23.229 36.508 33.815 48.0744 
42.3522 16.7238 35.651 42.449 42.9984 
51.4494 16.4502 27.196 32.356 46.6668 
45.5094 19.926 38.972 31.912 48.4794 
42.9372 18.0054 31.427 32.491 40.0896 
44.3214 23.1246 31.146 39.112 40.5522 
50.2614 19.2978 27.196 34.074 41.3982 
46.5714 23.9256 60.759 38.774 25.6464 
49.6206 28.314 33.522 41.955 47.2536 
51.0336 15.516 36.68 45.155 42.6042 
50.1912 27.6858 33.815 34.363 42.5412 
47.2914 34.3134 37.037 31.427 45.918 
46.647 27.5976 31.427 37.067 37.5462 
49.6206 30.5568 29.998 34.712 45.6066 
41.1822 15.9696 29.518 42.112 40.3092 
45.5688 22.9986 34.363 33.783 39.6432 
47.5902 20.493 31.146 41.745 52.0686 
41.7618 14.841 55.689 33.783 36.27 
44.0802 17.991 32.049 40.868 39.2148 
45.4122 18.4086 44.568 36.799 44.4024 
54.144 17.0136 36.59 34.554 48.5334 
25.3332 18.8874 37.973 34.586 42.9372 
44.9784 29.8368 38.233 35.121 24.0372 
50.6664 16.8012 37.067 41.163 44.3214 
48.0006 34.272 41.955 34.106 38.205 
43.9992 17.6328 31.146 41.587 39.6432 
36.099 14.6286 40.868 40.027 41.1606 
36.3924 16.7184 33.783 32.894 51.2244 
 
 
44.82 18.7344 36.799 40.976 45.5688 
43.6752 21.834 38.774 43.192 36.2214 
42.9372 15.7554 37.126 40 45.6066 
45.9756 14.724 34.074 28.765 46.6866 
22.6674 10.0314 25.915 35.679 36.2214 
48.663 12.4272 37.944 32.894 50.1192 
54.927 30.9402 31.252 41.508 44.8002 
53.3502 29.2122 43.268 37.771 44.1414 
52.6122 17.7318 39.112 24.117 52.5438 
46.6866 13.1238 34.681 32.626 41.526 
49.977 41.9292 38.519 33.815 44.4024 
53.082 35.9982 40.68 34.586 39.3732 
50.7726 21.5154 39.112 44.197 39.5748 
46.5714 17.7426 34.106 40.301 42.9372 
49.7826 18.3762 30.506 37.155 49.4766 
48.9168 34.7004 31.912 38.519 42.1632 
47.7954 28.8594 32.626 27.237 45.8208 
44.721 22.0572 34.203 43.065 53.748 
48.4794 21.2832 29.106 37.712 55.6812 
 
Other particle sizes and measurements 
Particle size. 
combination 
method (n=100) 
Particle size. 
bulk  
 
(n=100) 
Process particle  
size (n=100) 
 
Batch 1   Batch 2     Batch 3 
 
Thickness of 
shells. 
collected 
(n=100) 
Thickness of 
shells. 
process 
(n=100) 
145.526 41.103 
 
257.24 198.78 218.07 4.814 1.084 
288.976 43.524 230.01 186.54 191.08 5.589 1.533 
169.396 16.756 223.24 189.63 201.42 6.391 2.763 
135.248 17.285 305.95 198.78 215.92 4.152 2.423 
138.491 26.841 240.04 190.81 210.9 5.058 1.713 
370.117 18.946 235.79 177.53 193.44 5.236 2.167 
75.123 43.371 261.73 193.53 206.01 4.814 1.713 
74.495 53.929 229.36 195.74 209.79 4.785 2.763 
79.807 55.962 235.71 198.99 211.1 4.902 1.533 
266.601 12.222 307.18 217.47 205.71 5.639 2.423 
130.754 11.489 211.81 216.09 196.89 5.035 2.57 
145.892 23.193 260.66 213.21 202.78 4.731 3.089 
113.862 39.472 233.14 217.15 196.51 6.162 2.763 
143.651 52.068 233.32 205.14 198.31 5.748 1.916 
92.975 88.003 217.64 205.1 212.09 5.834 1.58 
258.719 12.708 236.25 177.61 200.18 7.097 1.626 
254.849 17.166 219.78 199.15 204.44 7.283 1.58 
 
 
278.883 39.628 251.43 212.31 212.09 5.547 1.381 
158.24 28.202 214.09 188.64 194.66 6.15 2.234 
141.605 16.801 248.93 193.65 184.91 6.131 2.682 
99.86 20.253 253.84 183.59 198.42 5.445 2.331 
67.912 13.116 258.86 210.19 183.74 6.112 2.234 
43.081 25.767 236.09 220.57 209.97 6.614 2.709 
261.262 14.207 236.9 468.25 206.19 5.436 1.533 
422.823 53.602 254.72 372.02 205.14 5.743 1.533 
431.021 60.208 249.98 379 200.35 4.58 2.167 
184.017 17.841 266.2 384.62 223.43 3.886 1.533 
194.775 40.123 255.49 362.01 188.44 6.266 2.167 
148.461 19.504 249.53 350.76 212.97 6.478 1.533 
233.581 36.034 224.49 365.78 215.92 5.785 3.427 
222.314 63.021 234.12 383.06 207.64 3.452 1.713 
182.23 15.494 280.36 387.68 276.59 10.575 1.713 
259.392 8.917 223.99 395.44 214.61 9.463 4.468 
84.216 10.949 218.18 295.17 209.79 5.436 1.713 
67.634 6.498 322.95 212.09 220.95 4.99 1.713 
43.457 8.377 306.68 211.16 193.44 6.299 1.713 
44.222 31.048 192.05 203.34 216.41 5.634 2.763 
25.912 32.115 231.55 222.63 225.93 4.72 3.159 
70.072 48.659 252.27 207.77 216.24 7.968 1.533 
248.417 55.486 238 194.66 224.91 11.105 2.763 
259.327 52.423 244.59 209.03 198.21 9.96 0.766 
77.304 22.685 242.83 197.62 212.25 8.287 1.713 
212.144 10.17 231.17 199.97 201.23 6.443 1.084 
124.43 27.448 239.1 226.07 194.66 10.187 1.713 
90.614 14.628 238.53 191.69 201.23 6.653 3.427 
131.048 19.216 241.26 212.31 207.16 5.873 2.423 
69.52 36.66 220.57 192.76 192.76 8.287 2.57 
92.843 7.4772 246.67 215.92 218.93 8.157 2.299 
178.72 13.932 262.64 198.21 218.93 5.768 2.57 
94.134 20.062 250.88 189.63 181.69 9.112 1.626 
88.434 49.71 223.26 222.99 234.18 6.653 1.626 
82.882 59.041 235.71 217.21 205.53 9.945 1.626 
123.182 64.629 226.59 206.35 215.83 4.942 1.724 
85.537 60.766 231.14 211.81 216.24 5.094 2.57 
56.163 18.523 234.06 218.84 221.48 6.744 2.874 
138.189 6.71 260.39 197.74 196.89 6.467 2.072 
213.11 9.072 212.09 232.9 205.6 10.187 1.149 
214.819 12.373 248.08 208.31 239.02 10.627 2.57 
63.756 20.093 190.91 234.12 200.37 5.094 1.149 
6.376 21.241 218.67 210.39 201.19 7.222 1.626 
 
 
37.066 27.712 254.54 216.52 205.14 6.529 3.448 
45.975 9.858 235.79 211.1 206.33 6.065 2.299 
266.685 8.48 218.93 192.56 205.51 3.497 1.713 
182.874 21.43 261.82 211.03 196.89 4.89 1.084 
175.351 27.667 237.37 229.77 218.41 6.529 0.766 
129.735 35.683 251.62 226.24 215.4 8.064 0.766 
225.916 11.367 250.88 226.3 201.83 5.425 2.423 
152.649 5.682 238.02 218.93 183.31 7.222 1.713 
84.242 18.253 221.62 207.16 190.41 8.12 1.713 
188.316 32.004 231.55 188.91 198.99 5.711 1.149 
188.779 44.197 216.24 210.9 218.84 5.95 1.626 
387.105 13.386 247.03 212.42 201.21 7.264 1.149 
206.487 8.114 222.38 193.65 193.07 8.854 2.299 
114.561 64.654 239.72 222.23 215.13 5.237 2.299 
261.685 78.881 249.44 217.13 140.71 6.407 2.299 
265.21 85.064 228.23 220.95 207.64 2.624 2.57 
76.769 57.074 232.19 225.55 194.78 5.249 2.57 
153.698 7.979 231.87 229.68 198.09 10.821 2.57 
185.872 40.771 255.07 218.07 204.44 10.097 1.533 
38.517 20.093 231.63 197.74 194.5 7.423 2.299 
164.393 40.131 234.06 213.02 195.81 10.498 2.763 
150.234 9.538 235.02 244.13 198.78 7.873 2.423 
116.304 48.929 246.02 205.71 206.19 8.216 1.533 
168.708 34.425 238.85 235.49 210.45 9.167 2.299 
137.712 20.649 224.43 213.98 199.55 10.097 2.423 
172.757 6.13 248.78 234.12 205.53 8.939 3.251 
142.848 28.688 233.08 197.74 207.28 5.868 1.713 
164.819 8.037 231.71 208.71 190.41 8.464 3.251 
132.682 43.898 210.9 224.89 192.47 10.028 2.167 
100.384 68.023 243.15 220.2 197.36 11.737 1.713 
59.962 63.54 238.85 228.54 201.42 9.463 1.713 
100.384 12.029 235.24 230.68 201.39 9.39 1.713 
308.61 23.07 228.23 220.61 204.98 6.844 2.167 
67.431 44.137 216.93 224.56 361.56 5.868 3.159 
115.83 35.604 233.54 213.39 235.3 10.028 3.065 
173.78 30.405 222.23 212.95 215.66 7.139 1.713 
151.242 10.573 218.95 220.2 214.72 11.969 2.763 
174.051 47.617 207.97 219.72 217.66 8.939 3.089 
139.847 17.771 222.63 212.97 206.19 7.515 2.453 
226.695 37.366 246.5 204.44 209.76 10.097 3.089 
 
 
 
 
4-week stability studies 
Batch 1 (n=100) 
Day 0 Day 1 Day 3 Day 7 Day 14 Day 21 Day 28 
43.6752 45.2934 44.3214 34.4088 56.016 39.7764 64.089 
47.4786 54.144 37.071 40.8132 58.8024 41.7402 59.4432 
51.777 50.4036 37.7352 35.2008 64.0134 40.1112 64.8594 
44.82 47.2914 38.205 39.6432 51.777 32.2488 54.6588 
50.049 49.6206 41.4198 17.0748 56.3958 39.3948 58.2264 
49.3506 46.2258 38.7594 52.272 68.7276 44.1612 55.5264 
58.0878 50.6844 39.7764 45.5094 66.6666 37.7118 55.4868 
44.82 50.1912 33.993 37.9008 50.9112 37.7586 50.8428 
48.3138 45.5094 44.1414 35.8758 34.8966 39.5748 54.2358 
44.0208 47.1402 40.3542 37.7118 54.2916 41.1606 54.8856 
53.2836 51.9318 38.6658 41.6754 61.4628 39.9564 62.7156 
45.8784 44.8002 43.9992 39.7764 62.2548 40.1994 55.6866 
53.8146 44.4024 39.9564 39.4848 57.7044 50.1912 56.2194 
56.8512 45.117 48.5334 36.8784 30.2292 42.9372 47.3688 
51.9318 22.0698 41.3982 34.9992 49.4946 45.5688 56.9862 
46.971 49.977 42.6042 34.8966 60.2514 41.868 50.8464 
19.8216 46.2078 38.1816 42.1632 56.9592 50.049 53.757 
42.4368 49.0626 40.7052 38.7594 61.767 45.117 53.676 
47.4786 49.3506 37.143 42.687 37.071 45.117 51.6618 
42.1632 49.9248 37.5714 37.9008 58.5756 51.0336 58.437 
39.7764 24.8022 39.9996 34.9992 50.2092 41.8464 51.1506 
45.5094 48.9168 35.3016 34.1766 53.334 44.4024 55.728 
42.9372 45.117 34.6914 43.0398 57.4416 42.9372 49.4946 
53.1324 44.82 38.8728 36.3924 34.6662 46.5138 59.1084 
48.1662 48.0924 42.3738 35.901 56.016 42.687 54.9558 
49.977 44.82 49.4946 38.8728 56.7252 42.5214 56.0628 
41.868 48.9168 40.1112 38.9412 52.5942 39.6432 51.0174 
43.4106 41.4828 40.7916 13.131 34.1496 35.226 56.5902 
50.7726 49.4946 38.6658 31.6926 37.5462 44.3214 53.154 
51.2946 43.6752 37.7586 41.4828 64.0278 45.9756 56.8152 
43.9794 49.1886 37.0458 42.9372 63.3438 41.868 56.574 
50.7726 45.4122 42.75 43.7364 47.1402 40.5522 56.8674 
46.971 48.8988 48.663 37.9008 56.2698 44.4024 49.8438 
54.927 60.6042 39.2364 40.4856 64.6776 44.82 33.1002 
48.9528 46.971 45.3528 51.4674 64.3464 46.5714 52.2792 
52.5276 46.6668 42.6672 34.7688 60.0156 49.0266 56.7684 
46.6668 45.3528 40.8132 41.4198 54.144 45.9756 51.8058 
47.4786 55.071 54.144 37.7118 53.5986 46.0332 60.1362 
47.7036 45.8208 39.3948 37.1898 64.0008 51.2244 55.5732 
 
 
53.6652 47.1402 44.0208 38.6892 50.6844 42.9372 55.5174 
45.6066 44.181 42.687 34.1766 48.5334 33.4404 51.6618 
41.8464 45.3528 41.4828 54.927 49.4766 24.5862 58.3038 
39.2148 41.7402 40.5522 38.205 62.6814 22.1904 44.3088 
53.1 45.9756 39.9564 48.1842 52.4772 41.1822 48.5082 
44.7012 49.4046 39.9996 41.868 33.7572 51.777 56.7486 
44.0802 53.9298 42.687 35.901 37.5462 40.0896 54.2286 
43.1838 49.7826 44.0802 38.8278 62.496 28.0314 27.5274 
39.3948 49.5486 49.4766 41.868 64.1394 46.8954 55.35 
50.7726 27.4878 45.6066 37.7118 54.405 41.355 60.444 
48.5334 55.2006 38.8728 42.1632 58.9392 39.2148 60.5898 
43.6752 47.7954 41.3982 43.533 52.7472 41.526 56.1186 
44.82 48.8988 37.3338 28.845 51.3108 38.7594 57.924 
52.7472 48.5334 35.7768 45.333 69.6024 44.3214 58.3038 
46.5714 54.2754 50.7366 48.0744 63.3852 43.6752 57.375 
42.3522 58.2102 34.1766 42.9984 30.1698 40.6386 54.477 
51.4494 46.5138 34.7688 46.6668 41.526 43.3692 56.3598 
45.5094 48.0744 40.9014 48.4794 60.3684 51.0516 51.7032 
42.9372 44.721 40.023 40.0896 60.2964 44.5626 51.3774 
44.3214 60.2964 46.5714 40.5522 53.55 40.8132 51.8472 
50.2614 46.8378 42.687 41.3982 49.6206 43.533 55.5732 
46.5714 53.1 39.7764 25.6464 51.1038 38.9412 55.1952 
49.6206 49.6206 47.3472 47.2536 50.1138 50.9472 52.5258 
51.0336 41.355 41.526 42.6042 60.3684 48.8988 56.9106 
50.1912 43.9992 48.8988 42.5412 61.29 47.2914 57.2886 
47.2914 53.3502 35.8758 45.918 52.7472 45.117 54.648 
46.647 45.8208 36.7812 37.5462 54.8622 39.9564 47.6136 
49.6206 44.7012 41.6538 45.6066 50.6844 46.8954 57.726 
41.1822 44.9784 43.6752 40.3092 56.9592 40.6386 57.15 
45.5688 44.3826 44.181 39.6432 50.7726 37.3572 56.5812 
47.5902 56.142 42.9984 52.0686 60.2964 37.9476 51.3684 
41.7618 49.3326 41.868 36.27 25.6464 44.3214 53.2332 
44.0802 57.888 39.9996 39.2148 27.3582 37.9008 51.8544 
45.4122 43.6752 43.4304 44.4024 39.9996 39.5982 50.9346 
54.144 49.5486 38.6892 48.5334 25.4736 40.8132 53.0586 
25.3332 47.7396 41.0742 42.9372 48.8988 40.6386 51.9462 
44.9784 49.3326 41.526 24.0372 47.3472 42.9372 56.9016 
50.6664 46.647 40.1112 44.3214 33.3342 42.5214 56.3292 
48.0006 51.2946 38.4822 38.205 58.6674 43.533 62.0784 
43.9992 52.8318 40.617 39.6432 38.7594 37.9008 57.15 
36.099 47.178 37.143 41.1606 30.6954 37.7118 56.7486 
36.3924 51.3108 47.1402 51.2244 33.993 39.7764 58.7286 
44.82 45.6066 39.6432 45.5688 33.993 43.533 56.9106 
 
 
43.6752 46.6866 41.526 36.2214 23.589 47.3472 33.2604 
42.9372 48.1662 41.0742 45.6066 36.3924 18.7146 61.3008 
45.9756 46.7424 42.9984 46.6866 55.6974 45.918 51.5358 
22.6674 47.1402 38.6658 36.2214 43.9794 38.8728 54.6156 
48.663 49.9248 40.8132 50.1192 56.9592 57.951 57.0762 
54.927 47.1402 42.4368 44.8002 62.6814 48.4614 53.64 
53.3502 43.0812 41.7402 44.1414 49.3506 43.9794 54.522 
52.6122 54.144 45.6066 52.5438 54.6822 40.4856 47.997 
46.6866 55.6974 40.7052 41.526 49.4046 38.9412 57.402 
49.977 42.9372 39.2148 44.4024 59.4036 44.82 24.4314 
53.082 46.3806 43.4106 39.3732 53.748 50.1912 31.563 
50.7726 44.5014 42.9984 39.5748 53.748 30.4038 55.8216 
46.5714 49.4766 49.4046 42.9372 56.0628 49.3326 52.137 
49.7826 53.8146 40.7052 49.4766 54.7308 42.75 58.1724 
48.9168 48.663 43.4106 42.1632 36 44.5014 54.2394 
47.7954 45.333 40.023 45.8208 45.6462 42.9984 54.639 
44.721 46.2258 44.82 53.748 62.8938 46.818 60.5664 
48.4794 48.0744 40.1112 55.6812 51.1038 47.7954 59.2002 
 
Batch 2 (n = 100) 
Day 0 Day 1 Day 3 Day 7 Day 14 Day 21 Day 28 
14.1426 19.3212 41.337 67.8258 50.445 31.1274 38.7594 
21.5928 17.055 20.6532 37.5696 26.586 43.9794 34.6914 
14.2956 19.6488 19.7964 40.1274 47.079 44.3214 29.2734 
28.0062 11.7702 9.8856 26.1036 26.2872 45.4122 21.7044 
21.8052 11.8872 22.5432 31.3704 38.034 46.5714 46.3806 
33.1272 15.0516 22.3038 40.743 24.8526 49.6026 45.5094 
21.87 16.2792 32.8248 39.1284 57.3786 42.9372 46.5714 
36.8658 17.1828 19.0152 41.4972 18.423 51.4674 31.6926 
23.9076 15.9588 19.4724 35.577 26.4042 51.5016 23.9994 
28.0152 32.643 10.8522 35.7768 54.675 43.0812 22.1904 
21.492 18.0882 30.3822 26.3988 32.4612 36.8784 36.4176 
17.973 19.0656 23.436 40.8132 51.8544 78.4746 49.8168 
35.5284 18.1458 22.3362 53.6814 30.4416 34.1766 38.7594 
26.1144 20.9898 17.9046 39.7764 30.9528 37.0458 45.6066 
21.5766 20.3562 14.4108 26.6994 28.251 40.617 26.667 
20.0142 14.3082 20.9484 28.3464 23.2794 40.1112 44.82 
44.1558 17.7966 24.0534 33.4404 24.903 29.2734 42.1632 
42.1308 16.848 22.3794 29.2428 26.586 42.687 42.1002 
18.5598 17.757 32.8536 36.0252 29.0754 21.4992 36.0252 
19.6434 28.5228 18.468 37.6416 23.4324 38.1816 75.8952 
19.2312 19.9782 18.2952 36.612 26.667 35.8758 44.181 
 
 
18.0054 17.9532 25.2522 25.0506 10.9494 36.3924 24.5862 
21.6252 30.8556 14.8608 20.0448 34.1892 37.7352 25.4736 
16.5762 15.075 16.3188 32.985 25.929 46.971 21.0816 
19.1754 23.499 22.3686 26.667 24.3414 37.5714 38.7594 
21.2994 17.9766 23.1624 41.355 30.771 48.4614 45.6462 
23.8266 23.3946 27.2628 24.5862 56.2302 31.1274 33.3342 
24.2442 18.9378 10.1772 26.6994 27.3978 41.4198 34.1496 
16.1496 16.5348 22.9302 28.2528 28.4706 24.4764 42.5214 
19.5912 19.926 26.5716 34.0722 32.3982 40.5522 42.3738 
17.1972 18.6912 27.1908 34.4088 10.2456 41.0742 30.2292 
18.2466 15.4638 23.4468 30.7818 29.871 42.5412 34.4088 
21.9294 17.6382 22.3794 30.9258 29.9952 52.272 46.5714 
15.0516 20.6802 23.1624 26.667 23.6556 34.6662 21.7044 
24.2442 17.4186 26.5626 37.3572 32.3226 44.181 54.9756 
37.1412 16.1496 24.1038 33.012 27.9864 46.2834 40.5522 
43.9956 17.4546 30.0906 27.3582 25.767 51.8634 29.1204 
19.4832 17.2638 11.3796 65.1294 27.6282 45.6066 34.1766 
36.4482 20.0142 17.5176 26.9982 27.8856 49.7826 49.1706 
26.9568 17.6184 12.8898 33.7572 24.678 30.4038 45.5094 
27.756 15.3288 11.6334 37.4292 34.4664 38.8728 48.0744 
40.5432 17.6328 12.582 24.0372 30.9528 73.7568 37.9476 
27.585 18.5508 21.6702 28.845 26.9802 39.033 64.0278 
37.3104 18.9 21.0762 24.0372 29.2446 40.0896 49.4766 
25.5096 19.2672 13.9806 26.6994 26.1972 41.355 53.1 
16.7652 16.128 10.8738 24.5862 31.4658 37.9008 33.3342 
16.9254 20.7558 25.8732 41.4828 26.8992 23.7402 24.0372 
15.2136 16.3008 8.8974 41.3982 29.9322 40.617 44.0208 
30.9204 25.0398 23.7366 28.782 21.8484 39.2148 33.651 
17.559 17.7318 20.5596 31.608 22.6854 41.6754 21.4992 
12.7944 22.1868 16.893 18.135 23.2794 43.6752 43.0398 
22.6044 17.856 33.5826 29.8134 37.6848 37.7118 42.75 
29.9214 18.2088 21.5334 26.6994 31.257 49.7826 25.4736 
23.229 19.6254 16.7904 18.8568 26.6148 46.5714 27.8406 
16.7238 20.0016 14.1372 33.3342 28.9026 29.1204 25.7508 
16.4502 22.4496 6.444 20.3958 21.438 50.1912 37.9242 
19.926 15.8832 10.485 19.6866 45.225 36.3924 42.75 
18.0054 17.5788 27.414 66.3048 29.0754 36.684 34.6914 
23.1246 19.3212 18.468 31.4676 24.1434 16.2756 48.9168 
19.2978 20.097 21.9384 36.684 28.7694 41.1822 42.9984 
23.9256 19.3626 23.4882 23.2848 13.1166 43.7364 24.9084 
28.314 16.9722 20.0178 30.7818 28.3986 45.5094 63.2322 
15.516 15.4188 19.8954 33.3342 24.6024 33.4404 30.0816 
27.6858 19.3626 28.0404 20.3094 28.7694 40.7052 26.6994 
 
 
34.3134 20.6874 32.1318 32.1102 28.962 78.1344 47.1402 
27.5976 19.3896 19.5732 26.9982 46.1052 16.7058 35.0748 
30.5568 16.7184 21.2598 28.0314 27.306 39.3948 43.4106 
15.9696 18.1458 19.422 30.4632 23.1786 47.2914 32.1102 
22.9986 18.432 20.9484 22.6674 26.2152 38.9412 43.7364 
20.493 16.56 19.3338 23.9994 30.0096 49.977 38.8728 
14.841 23.0184 22.2156 27.4554 39.1554 32.2488 33.993 
17.991 21.312 16.0776 43.0398 29.1762 46.2834 24.0372 
18.4086 18.3762 12.6018 31.212 28.0026 20.1762 24.0372 
17.0136 17.136 29.862 22.7052 28.935 45.117 38.1348 
18.8874 16.3062 19.1952 24.0372 29.2176 43.2666 50.1912 
29.8368 18.0054 20.1636 25.1568 30.1644 38.4822 39.9564 
16.8012 18.8118 23.4468 25.8894 29.367 38.6658 21.4992 
34.272 16.0578 34.281 18.8568 24.3738 28.6272 48.9168 
17.6328 16.848 20.3202 48.0924 31.77 36.7812 34.6158 
14.6286 20.7846 19.4724 32.1102 27.1692 30.6954 31.0986 
16.7184 28.449 20.0178 22.7844 27.3582 51.5196 31.1274 
18.7344 25.8048 20.9484 30.1698 22.0806 33.993 46.6866 
21.834 17.6382 22.293 28.7208 20.7396 21.0816 34.6158 
15.7554 17.46 15.6312 30.7818 28.9026 40.9014 20.6982 
14.724 18.9234 21.8502 32.985 35.964 43.0398 47.1402 
10.0314 33.1866 17.6418 37.6416 28.0026 27.8406 44.5014 
12.4272 19.8036 22.9302 31.0122 19.1916 33.3594 42.6672 
30.9402 18.5076 12.2076 9.4284 25.641 42.1632 34.2792 
29.2122 18.0306 16.6158 26.3988 23.9886 26.5662 35.2008 
17.7318 17.3196 27.2628 36.27 26.7948 37.143 48.1662 
13.1238 29.5542 20.97 28.0008 13.293 35.577 52.29 
41.9292 17.2782 24.2658 29.5146 33.2604 39.6432 45.3528 
35.9982 17.8902 27.2628 29.3328 30.159 37.7118 20.8692 
21.5154 18.0306 21.9492 24.5862 15.3324 36.612 27.4878 
17.7426 15.8832 25.9488 28.1268 18.2196 52.272 50.6844 
18.3762 16.4916 17.1378 25.6122 21.6774 32.0562 34.8966 
34.7004 20.3814 6.0138 40.1112 22.194 37.9008 41.7402 
28.8594 22.1526 18.5076 42.4368 17.0496 57.348 29.3634 
22.0572 31.1562 22.0716 40.5522 54.1368 46.647 46.8954 
21.2832 18.8586 18.5076 32.2758 28.9998 40.4856 43.9794 
 
Batch 3 (n = 50) 
Day 0 Day 1 Day 3 Day 7 Day 14 Day 21 Day 28 
14.4216 22.1238 19.3122 30.8394 33.1002 24.1758 29.871 
19.1052 35.1432 10.8198 22.8402 70.1478 30.6702 34.0344 
16.2792 21.6774 16.1604 25.5816 41.8284 17.9892 35.4258 
 
 
12.5388 26.586 21.762 12.8952 36.0342 39.33 30.366 
12.4128 9.225 21.9888 11.2194 15.9678 70.668 36.7632 
5.94 22.7394 24.444 12.4614 23.0184 14.6592 39.5712 
6.7392 35.892 25.047 15.012 18.9234 37.899 34.1766 
13.7106 30.897 25.713 11.0214 21.762 21.5046 33.4368 
47.5074 27.7128 22.8762 10.809 13.932 17.9118 23.4126 
22.8042 23.9886 15.939 10.071 14.2074 20.2626 19.5768 
26.4204 21.2202 14.5854 12.5064 12.9978 40.14 30.6558 
21.0942 20.619 12.222 11.4984 41.1714 43.4826 29.3184 
20.592 40.4712 14.6286 10.071 46.5246 34.0668 34.542 
19.8486 24.8526 17.8074 11.2932 31.887 58.176 41.3766 
19.8486 20.889 40.959 11.9556 64.3284 13.1166 45.3582 
21.0942 44.613 36.2232 11.1456 30.1392 26.3574 16.074 
18.4392 40.635 30.1392 13.5306 15.7824 18.2538 19.1754 
17.8038 21.1842 21.0654 15.012 19.6308 21.3588 35.8956 
16.9704 46.5876 20.4066 15.012 11.9268 12.708 36.819 
16.1244 42.3558 13.932 14.1156 13.932 46.3878 41.463 
16.1244 44.9298 17.7714 12.6918 11.061 29.6676 41.3316 
46.6686 34.3746 28.1142 10.9476 10.17 54.4104 23.3316 
20.5182 31.3758 16.9488 15.2676 35.4654 20.1384 38.6496 
13.4532 57.9906 17.7372 11.3418 44.8326 26.4042 37.5372 
14.9994 42.6924 24.0408 10.2996 53.6148 28.0026 31.887 
36.0702 26.7552 18.144 12.1032 23.6556 28.2186 39.1284 
19.8486 26.6148 43.4106 12.582 23.7618 14.031 18.0828 
26.0766 19.9368 22.1238 12.1032 32.0364 28.0638 45.7506 
14.9994 44.9226 22.7466 11.9664 32.004 24.678 38.745 
18.4392 45.3186 19.8432 15.561 26.2872 44.1126 14.6286 
16.155 42.5862 20.889 12.7998 15.3738 46.0116 35.091 
18.8676 32.7276 19.3446 13.3668 35.9424 27.1404 40.2246 
15.0336 28.9836 19.719 25.7958 30.2058 16.6248 23.6952 
22.8042 60.354 13.0104 13.3452 21.294 27.1746 31.842 
15.5556 42.21 13.797 11.8638 15.453 55.7964 25.3296 
17.7192 32.3658 51.7428 12.9492 12.8286 40.347 27.8532 
15.6528 25.731 81.9216 25.0614 26.6382 52.092 30.7368 
19.9998 27.981 28.296 12.9798 26.4042 35.496 35.1432 
36.0702 28.791 21.8484 8.5338 21.0654 15.1596 35.8776 
14.8662 40.0356 19.5048 22.7142 21.9618 24.7338 40.2012 
17.6922 22.0806 30.0096 10.809 16.4556 22.194 31.2282 
22.203 39.4056 40.185 11.0592 14.2074 36.9864 40.2354 
21.9312 37.287 20.2626 9.4518 17.946 25.2018 15.9678 
39.825 36.9396 13.707 12.339 18.4572 49.4694 56.0448 
16.155 9.0036 13.932 10.179 24.066 16.2288 39.9564 
21.0942 39.5712 43.0074 11.2932 31.941 39.0456 36.6498 
 
 
19.4166 27.7632 21.294 11.4768 31.6134 31.3308 42.0372 
18.8676 36.0864 36.4572 10.971 55.1898 34.0992 13.1526 
16.9992 26.856 11.3688 5.3532 90.6174 40.8672 26.7948 
14.0364 37.89 8.4636 10.0476 28.6884 21.798 41.103 
 
6-week stability studies 
Batch 1 (n = 100) 
 
Batch 2 (n = 100) 
Day 0 Day 28 Day 35 Day 42 Day 0 Day 28 Day 35 Day 42 
22.9842 91.9332 51.5016 54.5364 15.9804 30.5478 18.549 23.7402 
39.1554 75.2832 52.9506 52.092 17.3556 14.7546 20.1312 48.1842 
18.1692 45.918 50.9562 69.7752 17.5212 24.8778 35.3898 32.2218 
12.6036 42.687 53.8002 37.6848 13.4784 15.732 25.083 26.667 
11.781 57.4722 59.094 56.9106 18.9036 15.3018 14.031 17.8884 
11.7234 50.7366 70.8282 55.2492 15.588 18.7326 13.977 22.7052 
15.2046 37.3572 49.4604 56.8422 15.4188 14.7222 23.9634 24.5862 
8.1558 85.8006 51.0174 55.827 11.0214 15.4836 13.1526 35.0748 
11.5452 26.9658 51.6096 56.502 15.2406 14.8068 13.932 44.8002 
14.067 77.4018 52.8966 54.7524 17.8092 12.8664 15.2208 28.1268 
12.429 53.2332 52.5294 53.667 20.2374 22.0806 13.932 19.0908 
12.9492 25.4736 51.0174 51.7158 16.3872 19.062 13.932 23.2848 
12.627 59.2254 51.0048 25.2324 13.3974 49.7016 16.7274 36.612 
36.36 74.0574 57.204 32.148 12.24 22.2066 16.0452 20.0448 
37.1016 41.868 78.5934 44.8776 16.0056 20.6874 11.8476 24.3306 
24.9732 71.2188 50.4936 57.114 20.8782 21.294 14.5854 26.5662 
17.4276 28.0314 30.897 51.3972 15.2406 13.2102 16.1604 45.333 
18.8802 88.6446 56.0448 39.0132 19.341 25.047 27.7182 23.2848 
27.0648 69.8562 52.4574 62.505 19.3338 16.866 16.0848 34.7688 
20.952 34.6662 55.1898 58.779 15.4818 20.4444 20.4606 27.4878 
24.0084 18.666 47.9394 60.1866 16.7184 17.8416 24.5268 21.8682 
27.5922 73.4418 53.8146 86.2488 15.9444 27.5274 14.2074 17.7894 
35.7768 44.721 48.717 56.088 21.5964 21.6774 7.5798 25.7508 
21.1338 74.2122 51.7788 39.0618 13.3452 16.074 9.4896 29.2734 
15.1218 83.916 55.2186 59.7528 16.3116 25.8516 16.0452 22.6278 
15.1218 57.3948 56.1114 59.4198 16.4628 17.2764 13.3866 37.1898 
42.8544 42.6672 53.3268 57.537 18.1692 15.4134 14.2074 40.7916 
31.1274 49.0626 49.6566 61.8678 16.8822 15.453 20.8656 34.7688 
59.7618 74.6316 20.5056 65.5056 18.5958 16.2 23.3316 20.0448 
72.8964 60.3684 55.5264 27.6678 16.3782 16.2 14.6592 26.667 
122.9274 60.0156 49.6566 57.5316 18.9396 30.9528 12.4614 25.6464 
72.0126 58.2102 46.1826 56.7252 19.9224 13.1526 16.7274 25.6122 
65.3886 66.6792 49.7574 55.3086 25.0614 17.9712 15.1596 26.5662 
49.0266 40.9014 54.1962 52.9884 22.7628 15.0048 13.7628 28.2834 
 
 
57.2706 71.6778 32.922 56.3508 17.3646 16.3908 13.4208 26.1954 
112.0716 76.653 54.6156 39.1554 18.5292 16.9488 15.6132 22.7052 
50.6664 55.458 19.4958 52.8084 13.1076 16.4664 12.3732 31.8042 
35.865 67.3038 25.3296 54.63 13.5306 13.932 12.4614 28.1268 
34.9218 75.2004 14.9742 53.9442 17.7408 16.2468 13.7628 21.9906 
42.2064 62.4528 62.505 53.8362 14.8464 15.6042 15.1398 27.4878 
34.5618 71.5536 30.6702 49.6008 19.6794 17.3106 11.7162 24.5124 
13.671 64.0692 33.048 50.1552 20.6604 16.569 15.057 27.4878 
12.5928 21.0816 51.6618 55.719 25.5816 16.2 29.871 23.7402 
34.7004 21.0816 51.426 51.1056 27.2466 17.7012 20.3382 25.8894 
32.8464 25.0506 53.5212 66.9564 11.5452 17.7804 17.3106 31.383 
36.36 38.8728 50.0922 67.707 15.7284 20.0628 26.3394 29.3634 
34.974 45.4122 55.53 53.2944 18.9036 14.6286 16.7184 23.589 
35.838 22.7052 30.1392 54.0594 18.6696 12.708 16.9488 27.4554 
22.0248 25.3332 56.3508 61.5186 15.525 17.3556 15.6438 34.4088 
24.1686 74.9628 55.9728 60.7428 19.0836 16.2468 15.0462 23.9994 
36.0216 74.6316 49.851 73.2078 18.0396 14.328 21.9888 19.413 
33.9966 44.8002 72.0324 63.0684 18.1692 16.9488 15.7032 29.3328 
31.8384 73.0908 49.5972 39.8952 21.393 11.4894 23.2794 22.3506 
31.1976 51.8634 53.3358 65.817 15.4188 10.8198 13.932 17.8884 
35.406 22.7052 31.6512 57.8196 15.2046 16.1604 15.057 18.666 
35.9658 65.6046 28.377 61.9812 16.5798 16.7562 9.4734 20.1762 
30.9492 26.4654 29.2446 83.2212 21.6162 16.8012 12.4614 23.3244 
36.1476 76.5126 41.7654 21.762 24.4386 13.2462 6.687 29.9628 
35.7318 77.1606 49.8222 59.7852 20.169 17.2026 13.5702 18.8568 
36.6984 77.1606 48.132 59.5692 22.0248 14.994 17.3106 36.3924 
38.619 75.2472 50.6016 56.178 22.8582 26.7552 34.1586 19.8216 
34.974 77.1606 50.6592 58.779 18.5508 43.0002 22.9302 29.4534 
35.712 41.4198 45.7812 57.537 16.686 33.4044 31.0878 20.0448 
37.8378 64.2222 49.068 57.2886 21.6738 32.211 17.946 22.8222 
33.57 61.767 51.462 65.448 10.071 36.5094 21.438 34.7688 
12.1608 88.1622 31.7646 26.7732 19.7838 26.0082 18.7992 17.7894 
10.0854 64.0008 52.3314 25.713 25.992 23.643 12.8286 51.777 
13.4388 65.3328 49.3848 23.9688 18.1998 14.274 22.7322 28.0314 
31.4964 72.1728 41.5422 26.667 28.6632 39.6648 19.0206 36.27 
36.792 29.3634 50.3928 15.0048 16.5798 37.9476 12.7314 34.6662 
36.6426 52.0686 50.4198 61.224 15.2406 36.7974 20.0934 16.11 
35.9154 39.9564 34.4664 25.941 22.5684 15.8598 12.8664 24.5124 
10.0854 69.6024 41.9004 29.554 16.8102 15.7716 16.0452 25.8894 
37.7514 76.3614 27.6732 51.215 18.2592 14.031 14.994 24.4764 
7.8642 70.7796 56.9412 39.871 15.561 14.7222 10.0458 26.2638 
12.1608 46.053 48.1878 51.329 19.0836 19.6308 15.8598 27.8406 
13.149 68.832 21.7044 58.75 17.4276 13.2462 18.4572 21.375 
 
 
36.1134 70.8804 34.7166 58.44 15.9804 19.6308 13.707 31.6926 
39.4002 69.9966 56.3544 53.967 16.4628 12.3732 15.7626 45.6462 
34.0776 60.8094 51.7032 49.741 28.701 15.0876 19.7028 24.0372 
34.6374 74.727 52.3062 45.049 19.1988 21.177 26.7786 24.3306 
34.7166 58.545 49.851 38.722 19.3986 17.3106 20.6802 24.0372 
16.2594 64.512 61.0722 40.516 19.3338 37.4868 16.1604 19.9998 
10.0818 58.8024 54.2502 49.464 24.5466 38.322 24.8778 31.2408 
14.2578 65.0196 51.9336 56.679 19.4058 28.5462 21.0294 23.3244 
12.24 45.5094 51.0174 25.491 16.0488 12.9258 19.8432 31.383 
15.012 57.7188 52.4664 28.491 18.5364 38.4876 18.1944 35.3016 
6.399 58.6818 49.9068 26.124 17.9334 46.1736 24.885 45.333 
19.7838 69.1794 51.2514 46.667 20.6604 26.4042 25.9956 31.1274 
11.511 69.3846 51.1758 56.377 20.7936 21.9618 32.8986 31.8042 
9.8928 22.0698 53.2332 34.305 18.5958 13.3974 18.144 25.4736 
9.6246 20.1762 52.182 58.547 16.3782 18.2538 19.4652 21.8682 
10.2996 34.6662 52.7058 48.787 19.818 17.2854 14.994 25.8894 
21.5532 32.2488 52.3368 20.713 17.8938 37.3662 20.1852 28.5354 
20.2374 39.2148 48.6882 25.841 19.4616 34.3026 9.4734 23.2848 
23.2218 36.7812 47.4858 34.551 16.4124 34.425 16.3134 26.6994 
24.327 87.0354 53.8002 49.184 14.2614 15.9588 18.423 30.1392 
29.5182 73.9242 52.2414 44.193 18.9396 12.573 8.2278 16.7562 
28.9494 45.8784 49.2678 35.572 15.561 20.6262 26.7948 21.762 
48.3534 47.178 51.5142 45.016 19.2276 19.062 37.3752 10.3662 
 
Bulk particle stability 
Bulk batch (n=100) 
Day 0 Day 1 Day 3 
41.103 54.68 94.483 
43.524 47.313 80.573 
16.756 8.488 83.489 
17.285 61.678 71.586 
26.841 17.094 57.443 
18.946 38.64 34.752 
43.371 54.793 23.07 
53.929 50.934 10.99 
55.962 9.921 12.222 
12.222 8.65 23.018 
11.489 17.285 18.523 
23.193 19.504 14.628 
39.472 47.368 33.645 
52.068 11.433 28.427 
88.003 17.058 62.497 
 
 
12.708 66.673 35.548 
17.166 9.14 11.433 
39.628 22.546 57.661 
28.202 7.979 52.11 
16.801 38.143 5.817 
20.253 39.025 31.386 
13.116 25.689 48.738 
25.767 5.923 53.294 
14.207 5.682 20.253 
53.602 68.779 18.599 
60.208 77.257 10.719 
17.841 61.453 27.442 
40.123 57.8 34.392 
19.504 22.46 64.152 
36.034 11.284 13.293 
63.021 19.936 26.287 
15.494 54.561 7.477 
8.917 22.847 12.335 
10.949 9.14 10.045 
6.498 46.841 26.422 
8.377 11.06 23.392 
31.048 49.8 22.869 
32.115 34.466 34.012 
48.659 50.82 60.094 
55.486 20.062 23.988 
52.423 45.7 32.365 
22.685 58.181 57.234 
10.17 69.586 15.523 
27.448 63.304 78.28 
14.628 57.443 28.983 
19.216 16.54 10.819 
36.66 9.732 17.78 
7.4772 9.858 34.569 
13.932 7.741 27.009 
20.062 16.948 7.7616 
49.71 61.171 9.489 
59.041 18.381 55.686 
64.629 6.156 24.683 
60.766 3.389 30.664 
18.523 32.34 40.822 
6.71 60.226 18.558 
9.072 34.335 72.568 
12.373 23.727 75.24 
 
 
20.093 14.659 43.41 
21.241 34.909 6.982 
27.712 30.655 19.719 
9.858 41.421 24.519 
8.48 20.687 16.502 
21.43 13.797 40.921 
27.667 5.517 12.259 
35.683 6.229 8.227 
11.367 18.45 12.731 
5.682 1.762 33.496 
18.253 13.977 9.275 
32.004 4.057 14.839 
44.197 8.377 12.817 
13.386 14.065 14.097 
8.114 60.278 25.75 
64.654 31.152 7.853 
78.881 27.869 46.123 
85.064 6.687 47.763 
57.074 18.466 57.321 
7.979 11.104 64.153 
40.771 22.69 45.471 
20.093 17.622 25.232 
40.131 68.099 35.404 
9.538 5.572 19.191 
48.929 14.207 34.144 
34.425 29.662 45.678 
20.649 17.71 16.275 
6.13 10.704 5.599 
28.688 15.859 10.719 
8.037 30.695 32.779 
43.898 71.366 77.533 
68.023 5.817 35.395 
63.54 19.384 10.17 
12.029 15.139 7.048 
23.07 9.522 4.728 
44.137 6.687 44.056 
35.604 11.367 35.877 
30.405 21.682 5.137 
10.573 33.528 30.159 
47.617 31.77 23.806 
17.771 6.778 5.014 
37.366 11.755 76.903 
 
 
 
APPENDIX 3 
Dissolution tests 
BSA. Physical mixtures. no membrane. pH 7.2 - series 1 
Time 
(h) 
Concentration 
(µg/ml) 
Quantity of BSA 
taken in the 
sample (µg) 
Cumulative 
quantity to be 
added to the total 
quantity (µg) 
Total quantity of 
BSA (µg) 
Corrected 
concentration 
(µg/ml) 
Released 
BSA (%) 
0 0 0 0 0 0 0 
0.008 97.72297 97.72297 0 1954.5 97.723 62.312 
0.017 149.3252 149.3252 97.723 3084.2 154.21 98.331 
0.033 141.6996 141.6996 247.048 3081 154.05 98.229 
0.05 142.0427 142.0427 388.748 3229.6 161.48 102.97 
0.067 137.8074 137.8074 530.791 3286.9 164.35 104.79 
0.083 123.8877 123.8877 668.598 3146.4 157.32 100.31 
0.17 124.4125 124.4125 792.486 3280.7 164.04 104.6 
0.5 117.7142 117.7142 916.898 3271.2 163.56 104.29 
24 113.7183 113.7183 1034.61 3309 165.45 105.5 
48 113.7183 113.7183 862.227 3136.6 156.83 100 
       BSA. Physical mixtures. no membrane. pH 7.2 - series 2 
Time 
(h) 
Concentration 
(µg/ml) 
Quantity of BSA 
taken in the 
sample (µg) 
Cumulative quantity to be 
added to the total quantity 
(µg) 
Total 
quantity 
of BSA 
(µg) 
Corrected 
concentration 
(µg/ml) 
Released 
BSA (%) 
0 0 0 0 0 0 0 
0.008 71.53996 71.53996 0 1430.8 71.54 54.528 
0.017 137.3221 137.3221 71.54 2818 140.9 107.39 
0.033 130.3658 130.3658 208.862 2816.2 140.81 107.33 
0.05 124.054 124.054 339.228 2820.3 141.02 107.48 
0.067 119.1602 119.1602 463.282 2846.5 142.32 108.48 
0.083 113.7008 113.7008 582.442 2856.5 142.82 108.86 
0.17 109.2489 109.2489 696.143 2881.1 144.06 109.8 
0.5 104.8966 104.8966 805.392 2903.3 145.17 110.65 
24 92.69407 92.69407 910.288 2764.2 138.21 105.34 
48 92.69407 92.69407 770.087 2624 131.2 100 
       BSA. Physical mixtures. no membrane. pH 1.2 - series 1 
Time 
(h) 
Concentration 
(µg/ml) 
Quantity of BSA 
taken in the 
sample (µg) 
Cumulative quantity 
to be added to the 
total quantity (µg) 
Total quantity 
of BSA (µg) 
Corrected 
concentration 
(µg/ml) 
Released 
BSA (%) 
0 0 0 0 0 0 0 
0.008 28.13627 28.13627 0 562.73 28.136 24.109 
0.017 110.1351 110.1351 0 2202.7 110.14 94.37 
0.033 108.7848 108.7848 110.135 2285.8 114.29 97.931 
0.05 102.6724 102.6724 218.92 2272.4 113.62 97.354 
   
 
 
0.067 101.7011 101.7011 321.592 2355.6 117.78 100.92 
0.083 92.72462 92.72462 423.294 2277.8 113.89 97.587 
0.17 89.76396 89.76396 516.018 2311.3 115.56 99.022 
0.5 85.20962 85.20962 605.782 2310 115.5 98.966 
24 82.15631 82.15631 690.992 2334.1 116.71 100 
48 82.15631 82.15631 690.992 2334.1 116.71 100 
       BSA. Physical mixtures. no membrane. pH 1.2 - series 2 
Time 
(h) 
Concentration 
(µg/ml) 
Quantity of BSA 
taken in the 
sample (µg) 
Cumulative quantity to be 
added to the total quantity 
(µg) 
Total 
quantity 
of BSA 
(µg) 
Corrected 
concentration 
(µg/ml) 
Released 
BSA (%) 
0 0 0 0 0 0 0 
0.008 15.49369 15.49369 0 309.87 15.494 14.648 
0.017 103.4562 103.4562 0 2069.1 103.46 97.812 
0.033 104.132 104.132 103.456 2186.1 109.3 103.34 
0.05 96.27274 96.27274 207.588 2133 106.65 100.83 
0.067 93.3924 93.3924 303.861 2171.7 108.59 102.66 
0.083 86.99328 86.99328 397.253 2137.1 106.86 101.03 
0.17 84.9987 84.9987 484.247 2184.2 109.21 103.25 
0.5 79.55046 79.55046 569.245 2160.3 108.01 102.12 
24 73.33095 73.33095 648.796 2115.4 105.77 100 
48 73.33095 73.33095 648.796 2115.4 105.77 100 
       BSA. PCL particles. no membrane. pH 7.2 - series 1 
Time 
(h) 
Concentration 
(µg/ml) 
Quantity of BSA 
taken in the 
sample (µg) 
Cumulative quantity to be 
added to the total quantity 
(µg) 
Total 
quantity 
of BSA 
(µg) 
Corrected 
concentration 
(µg/ml) 
Released 
BSA (%) 
0 0 0 0 0 0 0 
0.008 4.16591 4.16591 0 83.318 4.1659 11.482 
0.017 4.71935 4.71935 4.16591 98.553 4.9276 13.581 
0.033 4.91937 4.91937 8.88526 107.27 5.3636 14.783 
0.05 4.61431 4.61431 13.8046 106.09 5.3045 14.62 
0.067 4.7245 4.7245 18.4189 112.91 5.6454 15.56 
0.083 4.1595 4.1595 23.1434 106.33 5.3167 14.654 
0.17 4.108 4.108 27.3029 109.46 5.4731 15.085 
0.5 3.72527 3.72527 31.4109 105.92 5.2958 14.596 
1 3.73186 3.73186 35.1362 109.77 5.4887 15.128 
2 3.4689 3.4689 38.8681 108.25 5.4123 14.917 
3 3.24235 3.24235 42.337 107.18 5.3592 14.771 
4 3.18639 3.18639 45.5793 109.31 5.4654 15.063 
5 2.86315 2.86315 48.7657 106.03 5.3014 14.612 
6 2.79732 2.79732 51.6289 107.58 5.3788 14.825 
24 2.52668 2.52668 54.4262 104.96 5.248 14.464 
 
 
48 3.32608 3.32608 56.9529 123.47 6.1737 17.016 
168 5.85314 5.85314 60.2789 177.34 8.8671 24.439 
336 3.0627 3.0627 66.1321 127.39 6.3693 17.555 
       BSA. PCL particles. no membrane. pH 7.2 - series 2 
Time 
(h) 
Concentration 
(µg/ml) 
Quantity of BSA 
taken in the 
sample (µg) 
Cumulative quantity to be 
added to the total quantity 
(µg) 
Total 
quantity 
of BSA 
(µg) 
Corrected 
concentration 
(µg/ml) 
Released 
BSA (%) 
0 0 0 0 0 0 0 
0.008 9.16496 9.16496 0 183.3 9.165 22.341 
0.017 8.97407 8.97407 9.16496 188.65 9.4323 22.993 
0.033 8.69918 8.69918 18.139 192.12 9.6061 23.416 
0.05 8.13028 8.13028 26.8382 189.44 9.4722 23.09 
0.067 7.72472 7.72472 34.9685 189.46 9.4731 23.092 
0.083 7.32723 7.32723 42.6932 189.24 9.4619 23.065 
0.17 7.36093 7.36093 50.0204 197.24 9.862 24.04 
0.5 7.02155 7.02155 57.3814 197.81 9.8906 24.11 
1 7.24978 7.24978 64.4029 209.4 10.47 25.522 
2 6.73477 6.73477 71.6527 206.35 10.317 25.15 
3 6.218 6.218 78.3875 202.75 10.137 24.711 
4 5.98418 5.98418 84.6055 204.29 10.214 24.899 
5 5.74378 5.74378 90.5897 205.47 10.273 25.043 
6 5.37211 5.37211 96.3334 203.78 10.189 24.837 
24 5.07204 5.07204 101.706 203.15 10.157 24.76 
48 4.10056 4.10056 106.778 188.79 9.4394 23.01 
168 9.77427 9.77427 110.878 306.36 15.318 37.34 
336 4.70005 4.70005 120.652 214.65 10.733 26.163 
       BSA. PCL particles. no membrane. pH 1.2 - series 1 
Time 
(h) 
Concentration 
(µg/ml) 
Quantity of BSA 
taken in the 
sample (µg) 
Cumulative quantity 
to be added to the 
total quantity (µg) 
Total quantity 
of BSA (µg) 
Corrected 
concentration 
(µg/ml) 
Released 
BSA (%) 
0 0 0 0 0 0 0 
0.008 4.01263 4.01263 0 80.253 4.0126 11.538 
0.017 10.07818 10.07818 4.01263 205.58 10.279 29.555 
0.033 10.13089 10.13089 14.0908 216.71 10.835 31.156 
0.05 9.81109 9.81109 24.2217 220.44 11.022 31.692 
0.067 9.38369 9.38369 34.0328 221.71 11.085 31.874 
0.083 9.28122 9.28122 43.4165 229.04 11.452 32.929 
0.17 9.74853 9.74853 52.6977 247.67 12.383 35.607 
0.5 8.67255 8.67255 62.4462 235.9 11.795 33.914 
1 8.14251 8.14251 71.1188 233.97 11.698 33.637 
2 8.11286 8.11286 79.2613 241.52 12.076 34.722 
3 7.65704 7.65704 87.3742 240.51 12.026 34.578 
 
 
4 7.1749 7.1749 95.0312 238.53 11.926 34.293 
5 6.63712 6.63712 102.206 234.95 11.747 33.778 
6 6.1443 6.1443 108.843 231.73 11.586 33.315 5 6.63712 6.63712 102.206 234.95 11.747 33.778 
24 0 0 114.99 114.99 5.749 33.315 6 6.1443 6.1443 108.843 231.73 11.586 33.315 
48 0 0 114.99 114.99 5.749 16.531        
 
        
 
 
